

Approved



**Kenya**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		0		0	1,100,000	1,100,000
USAID		279,205,924		279,205,924	12,875,999	292,081,923
DOD		22,057,792		22,057,792	0	22,057,792
PC		202,967		202,967	1,248,131	1,451,098
HHS/CDC	3,320,000	178,042,222		181,362,222	0	181,362,222
HHS/HRSA		1,846,964		1,846,964	0	1,846,964
State/AF		100,000		100,000	1	100,001
<b>Total</b>	<b>3,320,000</b>	<b>481,455,869</b>	<b>0</b>	<b>484,775,869</b>	<b>15,224,131</b>	<b>500,000,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		1,141,214	9,028,804				1,394,844	0	11,564,862
HBHC	0	2,735,135	22,417,747	60,455		25,000	18,641,522	0	43,879,859
HKID	0	1,198,270	617,107		12,922	75,000	29,967,437	0	31,870,736
HLAB		1,652,568	9,417,360	350,000			2,548,247	0	13,968,175
HMBL			1,687,348				858,649	0	2,545,997
HMIN			1,548,020				99,013	0	1,647,033
HTXD			560,000				92,094,295	0	92,654,295
HTXS		5,578,837	53,226,374	242,290			50,765,205	0	109,812,706
HVAB		48,394	372,354	546,964	59,546		1,731,885	0	2,759,143

Approved



HVCT		2,150,632	13,673,662				14,272,662	0	<b>30,096,956</b>
HVMS	0	2,115,647	11,751,078		121,185		8,441,336	0	<b>22,429,246</b>
HVOP		835,940	8,508,790		8,321		5,236,647	0	<b>14,589,698</b>
HVSI	0	1,366,790	12,513,886	600,000			10,403,265	0	<b>24,883,941</b>
HVTB		639,814	7,291,507	19,034			6,844,823	0	<b>14,795,178</b>
IDUP		1,120	2,351,125				1,506,105	0	<b>3,858,350</b>
MTCT		1,704,043	11,909,541		993		10,284,561	0	<b>23,899,138</b>
OHSS	0		3,638,581				5,981,503	0	<b>9,620,084</b>
PDCS		563,290	4,330,313	11,288			4,040,037	0	<b>8,944,928</b>
PDTX		326,098	6,518,625	16,933			14,093,888	0	<b>20,955,544</b>
	<b>0</b>	<b>22,057,792</b>	<b>181,362,222</b>	<b>1,846,964</b>	<b>202,967</b>	<b>100,000</b>	<b>279,205,924</b>	<b>0</b>	<b>484,775,869</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	43,245,785	0
HKID	31,422,042	0
HVTB	14,408,820	0
PDCS	8,511,413	0
<b>Total Technical Area Planned Funding:</b>	<b>97,588,060</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	13,152,759	0
HVSI	23,260,000	0
OHSS	8,000,000	0
<b>Total Technical Area Planned Funding:</b>	<b>44,412,759</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	11,287,590	0
HMBL	2,500,000	0
HMIN	1,500,000	0
HVAB	2,523,627	0
HVCT	29,289,008	0
HVOP	14,071,379	0
IDUP	3,628,577	0
MTCT	23,450,887	0

Approved



<b>Total Technical Area Planned Funding:</b>	<b>88,251,068</b>	<b>0</b>
--	-------------------	----------

**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	92,560,001	0
HTXS	108,796,401	0
PDTX	20,708,115	0
<b>Total Technical Area Planned Funding:</b>	<b>222,064,517</b>	<b>0</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,244,628
	Number of new ANC and L&D clients	1,257,432
	By: Known positives at entry	37,880
	By: Number of new positives identified	27,388
	Sum of Positives Status disaggregates	65,268
	Required only for DREAMS Countries - By Number of new positives: <15	28
	Required only for DREAMS Countries - By Number of new positives: 15-19	352
	Required only for DREAMS Countries - By Number of new positives: 20-24	1,413
	Required only for DREAMS Countries - By Number of known positives: <15	104
	Required only for DREAMS Countries - By Number of known	940



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	3,005
	Required only for DREAMS Countries - Denominator: <15	1,528
	Required only for DREAMS Countries - Denominator: <15-19	15,221
	Required only for DREAMS Countries - Denominator: 20-24	68,410
	Required only for DREAMS Countries - Denominator: 25-49	114,744
	Required only for DREAMS Countries - Denominator: 50+	12,267
	Required only for DREAMS Countries - By Number of known positives: 25-49	11,855
	Required only for DREAMS Countries - By Number of known positives: 50+	2,140
	Required only for DREAMS Countries - By Number of new positives: 25-49	5,218
	Required only for DREAMS Countries - By Number of new positives: 50+	801
	By Age (DREAMS SNU's ONLY): <15	1,573
	By Age (DREAMS SNU's ONLY): 15-19	14,969
	By Age (DREAMS SNU's ONLY): 20-24	66,386
	By Age (DREAMS SNU's ONLY): 25-49	111,835



	By Age (DREAMS SNU's ONLY): 50+	12,378
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,786
	Number of new ANC and L&D clients	87,880
	By: Known positives at entry	200
	By: Number of new positives identified	1,018
	Sum of Positives Status disaggregates	1,218
	Required only for DREAMS countries - By known positives: <15	
	Required only for DREAMS countries - By known positives: 15-19	
	Required only for DREAMS countries - By known positives: 20-24	
	Required only for DREAMS countries - By new positives: <15	
	Required only for DREAMS countries - By new positives: 15-19	
	Required only for DREAMS countries - By new positives: 20-24	
	Required only for DREAMS countries - Denominator: <15	





	Required only for DREAMS countries - Denominator: 15-19	
	Required only for DREAMS countries - Denominator: 20-24	
	Required only for DREAMS countries - Denominator: 25-49	
	Required only for DREAMS countries - Denominator: 50+	
	Required only for DREAMS countries - By known positives: 25-49	
	Required only for DREAMS countries - By known positives: 50+	
	Required only for DREAMS countries - By new positives: 25-49	
	Required only for DREAMS countries - By new positives: 50+	
	By Age (DREAMS SNU <sup>s</sup> ONLY): <15	
	By Age (DREAMS SNU <sup>s</sup> ONLY): 15-19	
	By Age (DREAMS SNU <sup>s</sup> ONLY): 20-24	
	By Age (DREAMS SNU <sup>s</sup> ONLY): 25-49	
	By Age (DREAMS SNU <sup>s</sup> ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,244,628
	New on ART	25,510
	Already on ART at beginning of current pregnancy	45,595
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,786
	New on ART	353
	Already on ART at beginning of current pregnancy	161
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	7,949
	Sex: Male	6,524
	Sex: Female	1,725
	Sum of Sex disaggregates	8,249
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the	240,010



	reporting period	
	By Age: 0-60 days	15
	By Age: 2 months - 9 years	307
	By Age: 10-14	139,723
	By Age: 15-19	60,268
	By Age: 20-24	13,747
	By Age: 25-29	20,469
	By Age: 30-49	5,239
	By Age: 50+	477
	Sum of age disaggregates (Prior to FY15)	214,215
	Sum of age disaggregates (FY15-Current)	239,923
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	234,892
	By circumcision technique: Device-based VMMC	5,500
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients	



	who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	16,215
	Male 10-14	
	Male 15-19	0
	Male 20-24	0
	Male 25-49	0
	Male 50+	0
	Female 10-14	
	Female 15-19	3,072
	Female 20-24	13,190
	Female 25-49	
	Female 50+	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	444,711
	Total number of people in the target population	667,657
	Age/sex: 10-14 Male	



	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	9,815
	Aggregated Age/sex: 15+ Male	147,317
	Aggregated Age/sex: <15 Female	32,287
	Aggregated Age/sex: 15+ Female	254,391



KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	165,600
	Total estimated number of key population in the catchment area	270,180
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,288
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,594
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are	0



	based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	128,563
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,448
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,208
	By key population type: People in prisons and enclosed settings	3,518



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	24,505
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	11,982
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	219,245
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	9,188
	By key population type: Females	5,414





	who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,855,752
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	167,822
	Age/sex: 15-19 Male	233,397
	Age/sex: 20-24 Male	421,430
	Age/sex: 25-49 Male	776,931
	Age/sex: 50+ Male	166,086
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	170,158
	Age/sex: 15-19 Female	266,444
	Age/sex: 20-24 Female	587,180
	Age/sex: 25-49 Female	1,120,294



	Age/sex: 50+ Female	215,738
	Test Result by Age and Sex: Positive: 10-14 Male	1,885
	Test Result by Age and Sex: Positive: 15-19 Male	4,636
	Test Result by Age and Sex: Positive: 20-24 Male	11,231
	Test Result by Age and Sex: Positive: 25-49 Male	23,531
	Test Result by Age and Sex: Positive: 50+ Male	5,393
	Test Result by Age and Sex: Positive: 10-14 Female	2,371
	Test Result by Age and Sex: Positive: 15-19 Female	6,258
	Test Result by Age and Sex: Positive: 20-24 Female	16,593
	Test Result by Age and Sex: Positive: 25-49 Female	37,259
	Test Result by Age and Sex: Positive: 50+ Female	7,675
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex:	



	Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	855,737
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,659,147
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	992,792
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,311,900
	Test Result by Aggregated Age and Sex: Negative <15 Male	2,111
	Test Result by Aggregated Age and Sex: Negative 15+ Male	14,369
	Test Result by Aggregated Age and Sex: Negative <15 Female	1,408
	Test Result by Aggregated Age and Sex: Negative 15+ Female	9,579
	Test Result by Aggregated Age and Sex: Positive <15 Male	17,035
	Test Result by Aggregated Age and Sex: Positive 15+ Male	88,692
	Test Result by Aggregated Age and Sex: Positive <15 Female	20,692
	Test Result by Aggregated Age and Sex: Positive 15+ Female	147,699
	Test Result by Age: Positive: <1	797



	Test Result by Age: Positive: 1-9	12,895
	Age/sex: <1	33,533
	Age/sex: 1-9	938,518
	Service Delivery Point (Community): Index testing	7,800
	Service Delivery Point (Community): Homebased testing	17,076
	Service Delivery Point (Community): Mobile testing	9,275
	Service Delivery Point (Community): Other	4,904
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	578,648
	Service Delivery Point (Facility): Outpatient	4,317,701
	Service Delivery Point (Facility): Pediatric	240,979
	Service Delivery Point (Facility):	21,591



	Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	367,257
	Service Delivery Point (Facility): VCT	1,828,384
	Service Delivery Point (Facility): VMC	97,869
	Service Delivery Point (Facility): PMTCT	1,061,895
	Service Delivery Point (Facility): TB Clinics	70,365
	Service Delivery Point (Facility): Index testing	206,051
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by	



	Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	503,099
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	2,010
	Age/sex: 15-19 Male	4,968
	Age/sex: 20-24 Male	14,169
	Age/sex: 25-49 Male	34,994
	Age/sex: 50+ Male	3,510
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	2,886
	Age/sex: 15-19 Female	6,865
	Age/sex: 20-24 Female	12,748



	Age/sex: 25-49 Female	28,107
	Age/sex: 50+ Female	2,927
	Test Result by Age and Sex: Positive: 10-14 Male	72
	Test Result by Age and Sex: Positive: 15-19 Male	56
	Test Result by Age and Sex: Positive: 20-24 Male	239
	Test Result by Age and Sex: Positive: 25-49 Male	715
	Test Result by Age and Sex: Positive: 50+ Male	68
	Test Result by Age and Sex: Positive: 10-14 Female	132
	Test Result by Age and Sex: Positive: 15-19 Female	155
	Test Result by Age and Sex: Positive: 20-24 Female	578
	Test Result by Age and Sex: Positive: 25-49 Female	1,617
	Test Result by Age and Sex: Positive: 50+ Female	172
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	



	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	27,060
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	127,131
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	35,146
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	258,350
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	514
	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,977
	Test Result by Aggregated Age and Sex: Positive <15 Female	737





	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,041
	Test Result by Age: Positive: <1	10
	Test Result by Age: Positive: 1-9	211
	Age/sex: <1	2,189
	Age/sex: 1-9	8,043
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	10,464
	Service Delivery Point (Facility): Outpatient	183,016



	Service Delivery Point (Facility): Pediatric	36,622
	Service Delivery Point (Facility): Malnutrition facilities	4
	Service Delivery Point (Facility): Other PITC	7,649
	Service Delivery Point (Facility): VCT	168,747
	Service Delivery Point (Facility): VMMC	1,725
	Service Delivery Point (Facility): PMTCT	108,648
	Service Delivery Point (Facility): TB Clinics	1,283
	Service Delivery Point (Facility): Index testing	1,177
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	



	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	75,176
	Total number of registered new and relapsed TB cases, during the reporting period.	76,483



	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,990
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34,619
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,660



	reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	34,885
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator:	



	Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,934
	Total number of registered new and relapsed TB cases, during the reporting period.	2,036
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator:	





	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and	



	relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	49
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	442
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,405
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	52,885
	Age/Sex: <10 Male	135
	Age/Sex: 10-14 Male	232
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	438
	Age/Sex: 25-49 Male	605
	Age/Sex: 50+ Male	67
	Age/Sex: <10 Female	519
	Age/Sex: 10-14 Female	8,144
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	14,770
	Age/Sex: 25-49 Female	1,391
	Age/Sex: 50+ Female	154
	Sum of Age/Sex Disaggregates	9,030
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	31,852
	By type of service: Sexual Violence (Post-Rape Care)	19,276
	By PEP service provision (related to sexual violence services provided)	13,678
	Age/Sex: 15-19 Female	14,595
Age/Sex: 15-19 male	212	
GEND_GBV_TA	Number of people receiving post-GBV care	14
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 20-24 Male	



	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
	By type of service: Sexual Violence (Post-Rape Care)	14
	By PEP service provision (related to sexual violence services provided)	14
	Age/Sex: 15-19 Female	
	Age/Sex: 15-19 Male	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	823,768
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	41,023
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	88,211
	Sum of Age/Sex disaggregates	129,234



	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	58
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	9,256
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	30,846
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	4,966
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	67
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,578
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	1,272
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	478
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
	Required only for DREAMS	1,361



	countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	29,068
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	12,886
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	1,160
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	67
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	2,594
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,276
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	490



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	129
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	3,793
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	10,370
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	9,735
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	66
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	2,578
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	1,271
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	479
	Required only for DREAMS	0





	countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	56
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	3,564
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	4,703
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	6,364
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	14,456
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	67
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	3,007
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,827
	Required only for DREAMS	820



	countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	1,357
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	21,712
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	31,213
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	25,410
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	67
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	3,859
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	2,541
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	11,939
	Required only for DREAMS	11,466



	countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	2,917
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	2,917
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	2,924
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	2,914
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	2,917
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	319,859
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	373,370
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS	2,859



	countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	2,831
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	3,626
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	2,902
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	4,582
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	27,387
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	29,971
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	967
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12,715
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	926
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12,896
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and	





	relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and	169



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	179
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male &lt;15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>4</p>
	<p>Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>58</p>
	<p>Aggregated Age/Sex: Female &lt;15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>5</p>
	<p>Aggregated Age/Sex: Female 15+ (Numerator: The number of</p>	<p>103</p>



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	





	period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,150,860
	Screened for TB by Age/Sex:<15 Male	52,470
	Screened for TB by Age/Sex: 15+ Male	353,568
	Screened for TB by Age/Sex:<15 Female	58,161
	Screened for TB by Age/Sex: 15+ Female	686,590
	Screen Result: Screened Positive for TB	173,565
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	151,491
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	4,474
	[Sub-Disagg of Specimen Sent]	146,556



	Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1,141
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,681
	Screened for TB by Age/Sex: <15 Male	346
	Screened for TB by Age/Sex: 15+ Male	1,956
	Screened for TB by Age/Sex: <15 Female	325
	Screened for TB by Age/Sex: 15+ Female	4,081
	Screen Results: Screened Positive for TB	157
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	157
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	157
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0



PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	48,812
	By infants who received their first virologic HIV test between 2 and 12 months of age	18,912
	Sum of Infant Age disaggregates	67,724
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	1,792
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	2,047



PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	129
	By infants who received their first virologic HIV test between 2 and 12 months of age	278
	Sum of Infant Age disaggregates	407
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	4
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	25



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,154,273
	Age/Sex: 15-19 Male	13,916
	Age/Sex: 15-19 Female	17,567
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	54,048
	Aggregated Age/Sex: 15+ Male	354,438
	Aggregated Age/Sex: <15 Female	57,514
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	688,260
	Sum of Aggregated Age/Sex <15	111,562
	Sum of Aggregated Age/Sex 15+	1,042,698
	Sum of Aggregated Age/Sex disaggregates	1,154,260
	Age/Sex: <1	2,312
	Age/Sex: <1-9	45,598
	Age/Sex: 10-14 Male	12,715
	Age/Sex: 10-14 Female	13,191
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	15,587
	Age/Sex: 25-49 Male	151,716
	Age/Sex: 50+ Male	54,155
Age/Sex: 20-24 Female	45,861	
Age/Sex: 25-49 Female	344,473	
Age/Sex: 50+ Female	71,784	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,080



	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	368
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	1,662
	Aggregated Age/Sex: <15 Female	346
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	3,707
	Sum of Aggregated Age/Sex <15	714
	Sum of Aggregated Age/Sex 15+	5,369
	Sum of Aggregated Age/Sex disaggregates	6,083
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	



	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	293,163
	By Age/Sex: <1	1,380
	By Age/Sex: 1-9	9,925
	By Age/Sex: 10-14 Male	2,370
	By Age/Sex: 15-19 Male	2,079
	By Age/Sex: 20-24 Male	4,799
	By Age/Sex: 25-49 Male	40,410
	By Age/Sex: 50+ Male	12,319
	By Age/Sex: 10-14 Female	2,792
	By Age/Sex: 15-19 Female	4,369
	By Age/Sex: 20-24 Female	14,742
	By Age/Sex: 25-49 Female	86,616
	By Age/Sex: 50+ Female	15,812
	Sum of Age/Sex disaggregates	186,308
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	12,320
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	88,986
	Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	13,145	
Aggregated Grouping by Age/Sex:	178,997	



	15+ Female	
	Sum of Aggregated Age/Sex disaggregates	293,448
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,349
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1 Male		





	Aggregated Grouping by Age/Sex: <15 Male	46
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	511
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	37
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	755
	Sum of Aggregated Age/Sex disaggregates	1,349
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,039,312
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records	1,076,786



	in the past 12 months.	
	Numerator: Indication: Routine	948,791
	Numerator: Indication: Targeted	50,942
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication:	



	50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	961,416
	Denominator: Indication: Targeted	58,556
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by	



	Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	48,686
	Numerator Aggregated Age/Sex: 15+ Male	323,264
	Numerator Aggregated Age/Sex: <15 Female	51,897
	Numerator Aggregated Age/Sex: 15+ Female	621,132
	Denominator Aggregated Age/Sex: <15 Male	50,832
	Denominator Aggregated Age/Sex: 15+ Male	331,244
	Denominator Aggregated Age/Sex: <15 Female	54,077
	Denominator Aggregated Age/Sex: 15+ Female	648,331
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12	n/a



	months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,472
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,080
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	



	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	





	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	4,480
	Numerator: Indication: Targeted	1,022
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	4,977
	Denominator: Indication: Targeted	1,135
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	



	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	



	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	321
	Numerator Aggregated Age/Sex: 15+ Male	1,532
	Numerator Aggregated Age/Sex: <15 Female	303
	Numerator Aggregated Age/Sex: 15+ Female	3,316
	Denominator Aggregated Age/Sex: <15 Male	360



	Denominator Aggregated Age/Sex: 15+ Male	1,658
	Denominator Aggregated Age/Sex: <15 Female	338
	Denominator Aggregated Age/Sex: 15+ Female	3,727
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	260,571
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	290,253
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,373
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,260
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,347
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at	1,876



	12 months after initiating ART	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,413
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36,344
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,092
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,703
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,960
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,325
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	77,806
	Age/Sex: 50+ Female (Numerator: Number of adults and children who	14,264



	are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,435
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,926
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,546
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,960
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	4,672



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39,996
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,058
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,884
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,233



	<p>Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>14,555</p>
	<p>Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>86,062</p>
	<p>Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>15,598</p>
	<p>Aggregated Age: &lt;15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)</p>	
	<p>Aggregated Age: &lt;15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the</p>	





	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,095
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78,962
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,926
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and	158,098



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,489
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	88,213
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,040
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	176,543
TX_RET_TA	TX_RET_TA Percent of adults and	n/a



	children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	980
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,377
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	



	ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	333
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	598
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	144





	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	457
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	732
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1,792



	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,792
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,434
	CD4: Number of laboratories that perform this testing	341
	CD4: Number of laboratories that participate in this PT program	341
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	273
	Early infant diagnostics: Number of laboratories that perform this testing	7
	Early infant diagnostics: Number of laboratories that participate in this PT program	7
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7
	HIV viral load: Number of laboratories that perform this testing	7
	HIV viral load: Number of laboratories that participate in this PT program	7
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7
	TB diagnostics (AFB microscopy):	1,500



	Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1,500
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,200
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	126
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	126
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	100
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	



	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	327
	CD4: Number of laboratories that participate in this PT program	305
	CD4: Number of laboratories that perform this testing	305
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	3
	Early infant diagnostics: Number of laboratories that perform this testing	3
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	0
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	0
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	3
	HIV viral load: Number of	3



	laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a	3,006



	result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	
	By Graduates: Doctors	13
	By Graduates: Nurses	1,392
	By Graduates: Midwives	0
	By Graduates: Social service workers	1
	By Graduates: Laboratory professionals	183
	By Graduates: Other	1,417
	Sum of Graduates disaggreagtes	3,006
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	8,699,516
	Number of HIV CD4 Reagents purchased	264,533
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	1,395,681
	Number of HIV ARVs purchased	
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	1,395,477
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	2,536,871
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	
	Condoms: Dollars planned (COP)/ spent (Actual)	
	HIV ARVs: Dollars planned (COP)/	

Approved



	spent (Actual)	
--	----------------	--



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
2866	CENTERS FOR HEALTH SOLUTIONS	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
7139	New Partner	TBD	U.S. Agency for International Development	GHP-State	1,200,000
7305	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	815,654
9108	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	896,964
9110	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	830,000
9136	International	NGO	U.S. Department	GHP-State	0





	Medical Corps		of Health and Human Services/Centers for Disease Control and Prevention		
9143	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	2,079,400
9171	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	12,125,987
11406	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	100,000
12054	CHF International	NGO	U.S. Agency for International Development	GHP-State	784,543
12056	Ananda Marga Universal Relief Teams	NGO	U.S. Agency for International Development	GHP-State	484,000
12083	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12530	Nyanza Reproductive Health Society	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12540	University of North Carolina	University	U.S. Agency for International	GHP-State	2,742,429



			Development		
12551	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12555	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12585	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12598	International Rescue Committee	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12605	Care International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



12637	Futures Group	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12656	Eastern Deanery AIDS Relief Program	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12658	Mkomani Society Clinic	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12664	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13025	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13050	Coptic Hospital	FBO	U.S. Department	GHP-State	0



			of Health and Human Services/Centers for Disease Control and Prevention		
13061	MINISTRY OF PUBLIC HEALTH AND SANITATION	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13179	Association of Schools of Public Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	595,000
13302	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13307	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13340	FHI 360	NGO	U.S. Agency for International	GHP-State	11,863,623



			Development		
13346	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
13354	Kenya Episcopal Conference	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13366	Christian Health Association of Kenya	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13385	University of Manitoba	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13399	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



13474	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13481	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13543	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13545	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	68,945
13546	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	3,853,364
13588	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	16,870,495
13636	JHPIEGO	University	U.S. Agency for International Development	GHP-State	8,690,200
13701	Kenya Medical Supplies Agency	Host Country Government Agency	U.S. Agency for International Development	GHP-State	143,391,701



13802	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13868	TBD	TBD	Redacted	Redacted	Redacted
13882	Children of God Relief Institute	FBO	U.S. Agency for International Development	GHP-State	1,647,637
13919	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	380,000
14009	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,250,000
14012	Moi Teaching and Referral Hospital	Parastatal	U.S. Agency for International Development	GHP-State	15,501,035
14015	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	1,662,500
14022	African Medical and Research Foundation	NGO	U.S. Agency for International Development	GHP-State	3,170,219
14034	Equity Group Foundation	NGO	U.S. Agency for International Development	GHP-State	0
16450	Kenya Community Development	NGO	U.S. Agency for International	GHP-State	380,386



	Foundation		Development		
16670	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,050,000
16679	International Business & Technical Consultants Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	400,000
16684	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,129,322
16687	Health Strat Kenya	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,593,199
16705	United Nations Office on Drug and Crime (UNODC)	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	1,402,765
16709	Center for Health Solutions (CHS)	NGO	U.S. Agency for International Development	GHP-State	1,500,000
16710	Equity Group Foundation	NGO	U.S. Agency for International Development	GHP-State	200,000





17190	Life Skills Promoters	NGO	U.S. Agency for International Development	GHP-State	968,000
17191	Reformed Church of East Africa	FBO	U.S. Agency for International Development	GHP-State	228,492
17707	PLAN International	NGO	U.S. Agency for International Development	GHP-State	6,515,991
17709	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	3,157,500
17711	National Blood Transfusion Service, Kenya	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	850,000
17712	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,550,000
17718	Interchurch Medical Assistance	FBO	U.S. Agency for International Development	GHP-State	8,134,682
17719	TBD	TBD	Redacted	Redacted	Redacted
17944	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,635,491
17945	mHealth Kenya	NGO	U.S. Department of Health and	GHP-State	780,000



			Human Services/Centers for Disease Control and Prevention		
17947	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,175,000
17948	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17950	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,520,000
17951	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,224,573
17954	Global Implementation Solutions	Implementing Agency	U.S. Department of Health and Human	GHP-State	3,100,000



			Services/Centers for Disease Control and Prevention		
17956	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	180,036
17958	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	2,850,000
17959	University of Nairobi	University	U.S. Agency for International Development	GHP-State	1,500,000
17960	Population Council	NGO	U.S. Agency for International Development	GHP-State	200,000
17964	University of North Carolina	University	U.S. Agency for International Development	GHP-State	250,000
18203	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	16,960,431
18204	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	3,285,296



			Prevention		
18205	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,223,928
18206	Kenya Conference of Catholic Bishops	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	11,006,593
18207	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,039,788
18208	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,842,084
18209	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,319,939



18213	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,357,688
18214	Palladium Group	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,900,000
18215	Coptic Hospital	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,341,355
18216	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	700,000
18217	County Government of Siaya	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,822,000
18223	University of	University	U.S. Department	GHP-State	2,750,000



	Maryland		of Health and Human Services/Centers for Disease Control and Prevention		
18260	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	350,000
18261	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	500,000
18262	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
18281	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	575,000
18283	TBD	TBD	Redacted	Redacted	Redacted
18284	TBD	TBD	Redacted	Redacted	Redacted
18285	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	100,000



18317	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	100,000
18318	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	2,850,000
18504	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,952,773
18505	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	13,515,808
18506	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	8,359,914
18507	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	4,714,291



			Control and Prevention		
18508	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,667,571
18509	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,380,424
18511	Christian Health Association of Kenya	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,400,770
18512	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,997,545
18513	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	4,097,153





			Prevention		
18514	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,240,703
18515	Eastern Deanery AIDS Relief Program	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,451,459
18516	Mkomani Society Clinic	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,847,393
18517	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 2866</b>	<b>Mechanism Name: DUMISHA/TEGEMEZA</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTERS FOR HEALTH SOLUTIONS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 2866</b>			
<b>Mechanism Name: DUMISHA/TEGEMEZA</b>			
<b>Prime Partner Name: CENTERS FOR HEALTH SOLUTIONS</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 7139</b>	<b>Mechanism Name: HP Plus</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,200,000</b>	
Funding Source	Funding Amount
GHP-State	1,200,000



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 7139			
<b>Mechanism Name:</b> HP Plus			
<b>Prime Partner Name:</b> New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 7305	<b>Mechanism Name:</b> Applying Science to Strengthen and Improve Systems-ASSIST
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 815,654</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 815,654</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	815,654

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 7305</b>			
<b>Mechanism Name: Applying Science to Strengthen and Improve Systems-ASSIST</b>			
<b>Prime Partner Name: University Research Corporation, LLC</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	320,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	295,654	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	0	0
-----------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9108</b>	<b>Mechanism Name: AIHA</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 896,964</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 896,964</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	896,964

### Cross-Cutting Budget Attribution(s)

Education	107,255
Gender: GBV	24,371
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	10,779
Focus Area:	Equity in HIV prevention, care, treatment and support
Human Resources for Health	329,285



### Budget Code Information

<b>Mechanism ID:</b> 9108			
<b>Mechanism Name:</b> AIHA			
<b>Prime Partner Name:</b> American International Health Alliance Twinning Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	546,964	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,705
PP_PREV_DSD	Total number of people in the target population	11,649
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	0
PP_PREV_DSD	Aggregated Age/sex: <15 Female	9,705
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	0
GEND_GBV_DSD	Number of people receiving post-GBV care	2,628
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	0
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	0



GEND_GBV_DSD	Age/Sex: 10-14 Female	2,628
GEND_GBV_DSD	Age/Sex: 20-24 Female	0
GEND_GBV_DSD	Age/Sex: 25-49 Female	0
GEND_GBV_DSD	Age/Sex: 50+ Female	0
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	2,628
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,972
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	540
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	156
GEND_GBV_DSD	Age/Sex: 15-19 Female	0
GEND_GBV_DSD	Age/Sex: 15-19 male	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,033
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	2,917
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0





	and sex: Education Support Male 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	7,033
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0



	and sex: Social Protection Female 25+	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	7,033



	and sex: Other Services Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	7,033
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0



	and sex: Social Protection Programs Female 1-9	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	0

**Implementing Mechanism Details**

<b>Mechanism ID: 9110</b>	<b>Mechanism Name: APHL</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 830,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 830,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	830,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	9110		
<b>Mechanism Name:</b>	APHL		
<b>Prime Partner Name:</b>	Association of Public Health Laboratories		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HLAB	600,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	80,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	341
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	341
LAB_PT_TA	CD4: Number of laboratories that perform this testing	341

### Implementing Mechanism Details

<b>Mechanism ID: 9136</b>	<b>Mechanism Name: IMC MARPS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Medical Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 9136			
<b>Mechanism Name:</b> IMC MARPS			
<b>Prime Partner Name:</b> International Medical Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 9143	<b>Mechanism Name:</b> Kenya Department of Defense
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 2,079,400	
<b>Applied Pipeline Amount:</b> 0	



<b>Total All Funding Sources and Applied Pipeline Amount: 2,079,400</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,079,400

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Commodities	60,890
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Renovation	35,294

**Budget Code Information**

<b>Mechanism ID: 9143</b>			
<b>Mechanism Name: Kenya Department of Defense</b>			
<b>Prime Partner Name: Henry Jackson Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	366,943	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	12,952	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	79,660	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	71,902	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	210,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	27,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	75,967	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	562,174	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	46,718	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	595,619	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	30,465	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,249
PMTCT_ART_DSD	New on ART	36
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	68
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,249
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,420



PMTCT_STAT_DSD	By: Known positives at entry	71
PMTCT_STAT_DSD	By: Number of new positives identified	38
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	109
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	500
VMMC_CIRC_DSD	By Age: 0-60 days	10
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	320
VMMC_CIRC_DSD	By Age: 15-19	35
VMMC_CIRC_DSD	By Age: 20-24	35
VMMC_CIRC_DSD	By Age: 25-29	35
VMMC_CIRC_DSD	By Age: 30-49	65
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	390
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	490
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	500
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	46,800
PP_PREV_DSD	Total number of people in the target population	150,000
PP_PREV_DSD	Aggregated Age/sex: <15 Male	4,602
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	18,923
PP_PREV_DSD	Aggregated Age/sex: <15 Female	4,602
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	18,673
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,751
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,870
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,650



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,647
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,584
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,517
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	28,234
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	32,751
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	55
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	353
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	58
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	413
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	3,506
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	9,607
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	3,632
HTC_TST_DSD	Service Delivery Point (Facility): VCT	11,267
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	1,229
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	3,176
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	334
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	172
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	172
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	109
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	4



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	296
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	163
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	133
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	81
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	81
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	49
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	28
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,077
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	130

TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,891
TB_SCREENDX_DSD	Screened for TB by Age/Sex: <15 Female	103
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,953
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	815
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	733
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	367
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	733
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	55
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	49
PMTCT_EID_DSD	Sum of Infant Age disaggregates	104
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,722
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	127
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,788
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	99
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,708
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	226
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,496
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,722
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	640
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	30
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	230
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	30



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	350
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	640
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,348
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,720
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	62
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,455
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	90
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,741
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	125
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,761
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	105
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,729
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	608
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	640
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	219
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	333



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	230
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	350

### Implementing Mechanism Details

<b>Mechanism ID: 9171</b>	<b>Mechanism Name: South Rift Valley</b>
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 12,125,987</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 12,125,987</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	12,125,987



**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	25,000
Food and Nutrition: Policy, Tools, and Service Delivery	10,000
Food and Nutrition: Commodities	25,000
Education	18,000
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Condom programming	50,000

**Budget Code Information**

<b>Mechanism ID:</b> 9171			
<b>Mechanism Name:</b> South Rift Valley			
<b>Prime Partner Name:</b> Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,704,195	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	721,464	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	398,848	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	350,170	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	1,450,098	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	450,390	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	1,023,048	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,783,725	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	197,826	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	1,041	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,130,944	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,747,313	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	166,925	0





## Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	105,368
PMTCT_ART_DSD	New on ART	1,855
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,213
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	105,368
PMTCT_STAT_DSD	Number of new ANC and L&D clients	105,371
PMTCT_STAT_DSD	By: Known positives at entry	1,052
PMTCT_STAT_DSD	By: Number of new positives identified	3,287
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,339
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	62
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	246
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	1,846
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	4,000
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	15,907
VMMC_CIRC_DSD	By Age: 10-14	6,791
VMMC_CIRC_DSD	By Age: 15-19	6,047
VMMC_CIRC_DSD	By Age: 20-24	1,834
VMMC_CIRC_DSD	By Age: 25-29	1,233



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	14,672
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	15,905
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	15,905
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,545
KP_PREV_DSD	Total estimated number of key population in the catchment area	5,730
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	208
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,337
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	510
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	5,220
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	479,508
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	40,483
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	199,625
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40,346
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	199,353



	ONLY: 15+ Female	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	80,829
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	398,978
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	479,807
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,773
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,089
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,720
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,960
HTC_TST_DSD	Age/sex: <1	6
HTC_TST_DSD	Service Delivery Point (Community): Index testing	7,800
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	17,076
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	9,275
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	19,998
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	187,005
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	9,661
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	411
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	96,898
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	14,818
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	103,001
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,631
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	13,120
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,418
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,406
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	136



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,072
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	143
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,057
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,538
OVC_SERV_DSD	Age/Sex: 18+ Male	2,940
OVC_SERV_DSD	Age/Sex: 18+ Female	3,597
OVC_SERV_DSD	Sum of Age/Sex disaggregates	6,537
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	7,112
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	6,889
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,100
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,325
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	346
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	42

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	671
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	44,849
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,065
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	13,089
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,150
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	27,546
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	7,786
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	797
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	496
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	402
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	67
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,931
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,934
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	44,851
TX_CURR_DSD	Age/Sex: 15-19 Male	11
TX_CURR_DSD	Age/Sex: 15-19 Female	20
TX_CURR_DSD	Sum of age/sex disaggregates	31
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,077
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,045



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,151
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	27,579
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,228
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	40,624
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	44,852
TX_CURR_DSD	Age/Sex: <1	4
TX_CURR_DSD	Age/Sex: <1-9	100
TX_CURR_DSD	Age/Sex: 10-14 Male	21
TX_CURR_DSD	Age/Sex: 10-14 Female	22
TX_CURR_DSD	Age/Sex: 20-24 Male	20
TX_CURR_DSD	Age/Sex: 25-49 Male	302
TX_CURR_DSD	Age/Sex: 50+ Male	102
TX_CURR_DSD	Age/Sex: 20-24 Female	82
TX_CURR_DSD	Age/Sex: 25-49 Female	697
TX_CURR_DSD	Age/Sex: 50+ Female	133
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,474
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	23
TX_NEW_DSD	By Age/Sex: 10-14 Male	6
TX_NEW_DSD	By Age/Sex: 15-19 Male	2
TX_NEW_DSD	By Age/Sex: 20-24 Male	6
TX_NEW_DSD	By Age/Sex: 25-49 Male	78
TX_NEW_DSD	By Age/Sex: 50+ Male	28
TX_NEW_DSD	By Age/Sex: 10-14 Female	6
TX_NEW_DSD	By Age/Sex: 15-19 Female	5
TX_NEW_DSD	By Age/Sex: 20-24 Female	20
TX_NEW_DSD	By Age/Sex: 25-49 Female	180
TX_NEW_DSD	By Age/Sex: 50+ Female	33
TX_NEW_DSD	Sum of Age/Sex disaggregates	364
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	546
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,399



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	572
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,936
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,453
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	50,837
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	50,517
TX_PVLS_DSD	Numerator: Indication: Routine	45,615
TX_PVLS_DSD	Numerator: Indication: Targeted	5,139
TX_PVLS_DSD	Denominator: Indication: Routine	45,313
TX_PVLS_DSD	Denominator: Indication: Targeted	5,082
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,249
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	14,858
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,411
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	31,222
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,233
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	14,758
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,395
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	31,009
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,288
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,251
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	379



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,453
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	393
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,058
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	407
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,446
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	393
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,034

**Implementing Mechanism Details**

<b>Mechanism ID: 11406</b>	<b>Mechanism Name: Community Grants Program</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted



Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 1</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,001</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

**Cross-Cutting Budget Attribution(s)**

Economic Strengthening	50,000
Education	50,000

**Budget Code Information**

<b>Mechanism ID: 11406</b>			
<b>Mechanism Name: Community Grants Program</b>			
<b>Prime Partner Name: U.S. Department of State</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	75,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12054</b>	<b>Mechanism Name: Healthy Outcomes through</b>
----------------------------	---



	<b>Prevention Education (HOPE)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CHF International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 784,543</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 784,543</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	784,543

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12054		
<b>Mechanism Name:</b>	Healthy Outcomes through Prevention Education (HOPE)		
<b>Prime Partner Name:</b>	CHF International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	784,543	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	603
PrEP_NEW_DSD	Female 15-19	115
PrEP_NEW_DSD	Female 20-24	488
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,483
PP_PREV_DSD	Total number of people in the target population	6,483
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	0
PP_PREV_DSD	Aggregated Age/sex: <15 Female	797
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	5,686
GEND_GBV_DSD	Number of people receiving post-GBV care	1,137
GEND_GBV_DSD	Age/Sex: 10-14 Female	239
GEND_GBV_DSD	Age/Sex: 20-24 Female	451
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	239
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	702
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	435
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	340
GEND_GBV_DSD	Age/Sex: 15-19 Female	447
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,166
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	432
OVC_SERV_DSD	Sum of Age/Sex disaggregates	432
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	159
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	969



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	150
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	477
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	894
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	720
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	720
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	477
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	720
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	450
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,734

### Implementing Mechanism Details

<b>Mechanism ID: 12056</b>	<b>Mechanism Name: Inuka Community Based OVC Project (ICOP)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ananda Marga Universal Relief Teams	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 484,000</b>	
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 484,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	484,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12056		
<b>Mechanism Name:</b>	Inuka Community Based OVC Project (ICOP)		
<b>Prime Partner Name:</b>	Ananda Marga Universal Relief Teams		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	484,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,000
OVC_SERV_DSD	Age/Sex: 18+ Male	351
OVC_SERV_DSD	Age/Sex: 18+ Female	440
OVC_SERV_DSD	Sum of Age/Sex disaggregates	791
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,999
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,210

### Implementing Mechanism Details

<b>Mechanism ID: 12083</b>	<b>Mechanism Name: Community HTC</b>
----------------------------	--------------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12083			
<b>Mechanism Name:</b> Community HTC			
<b>Prime Partner Name:</b> Liverpool VCT and Care			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12530</b>	<b>Mechanism Name: Provision of VMMC</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Nyanza Reproductive Health Society	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 12530</b>			
<b>Mechanism Name: Provision of VMMC</b>			
<b>Prime Partner Name: Nyanza Reproductive Health Society</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12540</b>	<b>Mechanism Name: MEASURE Evaluation</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,742,429</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,742,429</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,742,429

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12540		
<b>Mechanism Name:</b>	MEASURE Evaluation		
<b>Prime Partner Name:</b>	University of North Carolina		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	217,429	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	2,525,000	0





### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12551</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12551		
<b>Mechanism Name:</b>	Clinical Services		
<b>Prime Partner Name:</b>	University of California at San Francisco		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12555</b>	<b>Mechanism Name: Clinical Services/Centers of Excellence</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12555			
<b>Mechanism Name:</b> Clinical Services/Centers of Excellence			
<b>Prime Partner Name:</b> University of Nairobi			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12585</b>	<b>Mechanism Name: Eastern and Western Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 12585			
<b>Mechanism Name:</b> Eastern and Western Kenya			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)



**Implementing Mechanism Details**

<b>Mechanism ID: 12598</b>	<b>Mechanism Name: HIV Prevention in the General Population and Youth</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12598		
<b>Mechanism Name:</b>	HIV Prevention in the General Population and Youth		
<b>Prime Partner Name:</b>	International Rescue Committee		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Approved



Prevention	HVOP	0	0
------------	------	---	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12605</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 12605			
<b>Mechanism Name:</b> Clinical Services			
<b>Prime Partner Name:</b> Care International			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12637</b>	<b>Mechanism Name: Strengthening Strategic Information in Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	





<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12637		
<b>Mechanism Name:</b>	Strengthening Strategic Information in Kenya		
<b>Prime Partner Name:</b>	Futures Group		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12656</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Deanery AIDS Relief Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 12656</b>			
<b>Mechanism Name: Clinical Services</b>			
<b>Prime Partner Name: Eastern Deanery AIDS Relief Program</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12658</b>	<b>Mechanism Name: Clinical Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mkomani Society Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12658
<b>Mechanism Name:</b>	Clinical Services
<b>Prime Partner Name:</b>	Mkomani Society Clinic



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12664</b>	<b>Mechanism Name: Clinical Services</b>
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 12664</b>			
<b>Mechanism Name: Clinical Services</b>			
<b>Prime Partner Name: African Medical and Research Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13025</b>	<b>Mechanism Name: Integrated HIV Prevention Interventions Including Male Circumcision</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b>	13025		
<b>Mechanism Name:</b>	Integrated HIV Prevention Interventions Including Male Circumcision		
<b>Prime Partner Name:</b>	Impact Research and Development Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13050</b>	<b>Mechanism Name: Coptic Hospital / University of Washington Collaborative HIV Care Program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Coptic Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	0
-----------	---

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13050		
<b>Mechanism Name:</b>	Coptic Hospital / University of Washington Collaborative HIV Care		
<b>Prime Partner Name:</b>	Program Coptic Hospital		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0





### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13061</b>	<b>Mechanism Name: Advancement of Public Health Practices in Kenya</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: MINISTRY OF PUBLIC HEALTH AND SANITATION	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13061		
<b>Mechanism Name:</b>	Advancement of Public Health Practices in Kenya		
<b>Prime Partner Name:</b>	MINISTRY OF PUBLIC HEALTH AND SANITATION		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13179</b>	<b>Mechanism Name: Emory University</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Schools of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 595,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 595,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	595,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information



<b>Mechanism ID:</b> 13179			
<b>Mechanism Name:</b> Emory University			
<b>Prime Partner Name:</b> Association of Schools of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	595,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 13302	<b>Mechanism Name:</b> HIV Prevention Activities for Youth and General Population
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 13302			
<b>Mechanism Name:</b> HIV Prevention Activities for Youth and General Population			
<b>Prime Partner Name:</b> Hope Worldwide			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13307	<b>Mechanism Name:</b> Prevention for Youth and General Population
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 0	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13307			
<b>Mechanism Name:</b> Prevention for Youth and General Population			
<b>Prime Partner Name:</b> Impact Research and Development Organization			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13340	<b>Mechanism Name:</b> APHIAPlus Rift Valley
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 11,863,623	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 11,863,623	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	11,863,623



**Cross-Cutting Budget Attribution(s)**

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

**Budget Code Information**

<b>Mechanism ID: 13340</b>			
<b>Mechanism Name: APHIAPlus Rift Valley</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,831,612	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	1,308,721	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	603,754	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	332,338	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	382,359	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	1,560,771	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,787,386	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,703,927	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	352,755	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	144,094
PMTCT_ART_DSD	New on ART	2,272
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,187
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	144,094
PMTCT_STAT_DSD	Number of new ANC and L&D clients	148,771
PMTCT_STAT_DSD	By: Known positives at entry	2,165
PMTCT_STAT_DSD	By: Number of new positives identified	2,377
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,542
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,591





VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	7
VMMC_CIRC_DSD	By Age: 10-14	3,296
VMMC_CIRC_DSD	By Age: 15-19	3,064
VMMC_CIRC_DSD	By Age: 20-24	571
VMMC_CIRC_DSD	By Age: 25-29	448
VMMC_CIRC_DSD	By Age: 30-49	185
VMMC_CIRC_DSD	By Age: 50+	20
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	6,951
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	7,584
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	7,591
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	678,155
HTC_TST_DSD	Age/sex: 10-14 Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	26,329
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	219,281
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	25,307
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	407,238
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	51,636
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	626,519
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	678,155
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,074
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	5,430
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	933



	Female	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	10,535
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	49,664
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	296,423
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	51,928
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	48,833
HTC_TST_DSD	Service Delivery Point (Facility): VCT	79,809
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	7,591
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	141,415
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	2,429
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,910
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,102
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,216
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,050
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,542
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,152
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	17,758
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	19,910
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	64
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	194
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	36

	Female	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	380
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	301
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	12,289
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	1,860
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	1,702
HTC_TST_TA	Service Delivery Point (Facility): VCT	2,806
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	865
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_TA	Service Delivery Point (Facility): Index testing	86
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,065
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,484
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	227
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,339
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	134
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,365
GEND_GBV_DSD	Number of people receiving post-GBV care	1,330
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,330



GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,330
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	59,487
OVC_SERV_DSD	Age/Sex: 18+ Male	4,747
OVC_SERV_DSD	Age/Sex: 18+ Female	4,237
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,984
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	25,386
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	25,117
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,350
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,485
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	35
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	611
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	667
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	55,219

TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,948
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	15,721
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,135
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	33,415
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,775
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,775
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,775
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,762
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,178
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,940
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	54
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	110
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	55,219
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,708
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	15,473
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,602
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	34,436
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,310
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	49,909
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	55,219
TX_CURR_DSD	Age/Sex: <1	1
TX_NEW_DSD	Number of adults and children newly enrolled on	19,254



	antiretroviral therapy (ART)	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	963
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,307
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,176
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	11,808
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	19,254
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	49,698
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	55,219
TX_PVLS_DSD	Numerator: Indication: Routine	48,452
TX_PVLS_DSD	Numerator: Indication: Targeted	1,246
TX_PVLS_DSD	Denominator: Indication: Routine	53,834
TX_PVLS_DSD	Denominator: Indication: Targeted	1,385
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,438
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	13,928
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,343
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	30,989
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,708
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	15,473
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,602
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	34,436
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	16,734
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,254
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	8



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	836
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,621
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,023
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,254
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	963
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,307
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,176
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,808



**Implementing Mechanism Details**

<b>Mechanism ID: 13346</b>	<b>Mechanism Name: Support Services for HIV Pandemic</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	350,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13346		
<b>Mechanism Name:</b>	Support Services for HIV Pandemic		
<b>Prime Partner Name:</b>	World Health Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	51,991	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	16,369	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Care	PDCS	9,708	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	35,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	122,369	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	14,563	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13354</b>	<b>Mechanism Name: Kenya Conference of Catholic Bishops (KCCB)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Episcopal Conference	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13354			
<b>Mechanism Name:</b> Kenya Conference of Catholic Bishops (KCCB)			
<b>Prime Partner Name:</b> Kenya Episcopal Conference			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)



**Implementing Mechanism Details**

<b>Mechanism ID: 13366</b>	<b>Mechanism Name: Expanding High Quality HIV Prevention, Care and Treatment within Faith-Based Health Facilities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13366		
<b>Mechanism Name:</b>	Expanding High Quality HIV Prevention, Care and Treatment within Faith-Based Health Facilities		
<b>Prime Partner Name:</b>	Christian Health Association of Kenya		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13385</b>	<b>Mechanism Name: Prevention for MARPS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Manitoba	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13385			
<b>Mechanism Name:</b> Prevention for MARPS			
<b>Prime Partner Name:</b> University of Manitoba			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13399</b>	<b>Mechanism Name: Partnership for Advanced Care and Treatment (PACT)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 13399</b>
----------------------------



<b>Mechanism Name:</b> Partnership for Advanced Care and Treatment (PACT)			
<b>Prime Partner Name:</b> University of Maryland			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 13474	<b>Mechanism Name:</b> HIV Prevention for MARPS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13474		
<b>Mechanism Name:</b>	HIV Prevention for MARPS		
<b>Prime Partner Name:</b>	Hope Worldwide		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	0	0

**Implementing Mechanism Indicator Information**





(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13481</b>	<b>Mechanism Name: Prevention for MARPS-Central and Eastern</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13481</b>			
<b>Mechanism Name: Prevention for MARPS-Central and Eastern</b>			
<b>Prime Partner Name: University of Nairobi</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13543</b>	<b>Mechanism Name: PAMOJA</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13543			
<b>Mechanism Name:</b> PAMOJA			
<b>Prime Partner Name:</b> Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13545</b>	<b>Mechanism Name: Peace Corps</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 68,945</b>	
<b>Applied Pipeline Amount: 417,725</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 486,670</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	68,945

### Cross-Cutting Budget Attribution(s)

Economic Strengthening	1,000
Education	500



Water	1,000
Gender: GBV	1,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	1,500
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID:</b>	13545		
<b>Mechanism Name:</b>	Peace Corps		
<b>Prime Partner Name:</b>	U.S. Peace Corps		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	9,305	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	55,214	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	4,426	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
PP_PREV_DSD	Number of the target population who completed a	580



	standardized HIV prevention intervention including the minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	580
PP_PREV_DSD	Aggregated Age/sex: <15 Male	24
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	40
PP_PREV_DSD	Aggregated Age/sex: <15 Female	300
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	200
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	134
OVC_SERV_DSD	Age/Sex: 18+ Male	16
OVC_SERV_DSD	Age/Sex: 18+ Female	32
OVC_SERV_DSD	Sum of Age/Sex disaggregates	48
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	7
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	50



	and sex: Parenting/Caregiver Programs Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	24
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	24
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	16
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	44
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	20
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	90
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	12
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	30
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	24
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	14
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	6
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	4
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	12



	and sex: Other Services Male 25+	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	16
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	34
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	0

### Implementing Mechanism Details

<b>Mechanism ID: 13546</b>	<b>Mechanism Name: Kisumu West</b>
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,853,364</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,853,364</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,853,364

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	50,000
Food and Nutrition: Commodities	50,000
Key Populations: FSW	15,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients





Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	5,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID: 13546</b>			
<b>Mechanism Name: Kisumu West</b>			
<b>Prime Partner Name: Henry Jackson Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	462,280	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	342,714	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	100,356	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	90,583	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	464,610	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	45,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	116,613	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	361,113	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,779,097	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	90,998	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,505
PMTCT_ART_DSD	New on ART	476
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	437
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,505
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,505
PMTCT_STAT_DSD	By: Known positives at entry	233
PMTCT_STAT_DSD	By: Number of new positives identified	152
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	385
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	14
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	47
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	4



	known positives: <15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	24
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	55
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	36
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	155
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	1,035
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	1,812
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	467
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	74
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	30
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	56
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	15
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	36
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	155
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	1,035
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	1,812
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	467
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,174
PP_PREV_DSD	Total number of people in the target population	3,174
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,060
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,114



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	46,658
HTC_TST_DSD	Age/sex: 10-14 Male	1,128
HTC_TST_DSD	Age/sex: 15-19 Male	2,252
HTC_TST_DSD	Age/sex: 20-24 Male	5,593
HTC_TST_DSD	Age/sex: 25-49 Male	8,965
HTC_TST_DSD	Age/sex: 50+ Male	2,285
HTC_TST_DSD	Age/sex: 10-14 Female	1,501
HTC_TST_DSD	Age/sex: 15-19 Female	3,000
HTC_TST_DSD	Age/sex: 20-24 Female	6,342
HTC_TST_DSD	Age/sex: 25-49 Female	8,969
HTC_TST_DSD	Age/sex: 50+ Female	2,292
HTC_TST_DSD	Sum of Age/Sex disaggregates	42,327
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	69
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	141
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	352
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	548
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	135
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	68
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	141
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	353
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	553
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	138
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,299
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,052
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,667
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,640
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,966



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	39,692
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	46,658
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Male	2,111
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Male	14,369
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative <15 Female	1,408
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Negative 15+ Female	9,579
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	205
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,178
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	211
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,184
HTC_TST_DSD	Test Result by Age: Positive: <1	69
HTC_TST_DSD	Test Result by Age: Positive: 1-9	211
HTC_TST_DSD	Age/sex: <1	934
HTC_TST_DSD	Age/sex: 1-9	3,397
HTC_TST_DSD	Service Delivery Point (Community): Other	1,860
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,993
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	10,912
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,566
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	17,677
HTC_TST_DSD	Service Delivery Point (Facility): VCT	3,604
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	3,483
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	5,563
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	514
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	514



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	75
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	181
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	73
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	185
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,303
OVC_SERV_DSD	Age/Sex: 18+ Male	1,632
OVC_SERV_DSD	Age/Sex: 18+ Female	1,507
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,139
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	94
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	604
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	94
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	280
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	558
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	280
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	464
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	280



	and sex: Social Protection Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	93
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	319
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,726
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	8,272
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	10,462
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,165
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,999
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	130
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	130
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	41
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	45

TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	11,768
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	526
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,416
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	550
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	7,276
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	9,441
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	9,441
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	941
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8,220
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	280
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	215
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	516
PMTCT_EID_DSD	Sum of Infant Age disaggregates	731
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	56
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	149
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	11,768
TX_CURR_DSD	Age/Sex: 15-19 Male	86
TX_CURR_DSD	Age/Sex: 15-19 Female	155
TX_CURR_DSD	Sum of age/sex disaggregates	241
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	526
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,416
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	550





TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	7,257
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,076
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	10,673
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	11,749
TX_CURR_DSD	Age/Sex: <1	42
TX_CURR_DSD	Age/Sex: <1-9	698
TX_CURR_DSD	Age/Sex: 10-14 Male	168
TX_CURR_DSD	Age/Sex: 10-14 Female	174
TX_CURR_DSD	Age/Sex: 20-24 Male	217
TX_CURR_DSD	Age/Sex: 25-49 Male	2,299
TX_CURR_DSD	Age/Sex: 50+ Male	814
TX_CURR_DSD	Age/Sex: 20-24 Female	640
TX_CURR_DSD	Age/Sex: 25-49 Female	5,428
TX_CURR_DSD	Age/Sex: 50+ Female	1,047
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,462
TX_NEW_DSD	By Age/Sex: <1	7
TX_NEW_DSD	By Age/Sex: 1-9	144
TX_NEW_DSD	By Age/Sex: 10-14 Male	36
TX_NEW_DSD	By Age/Sex: 15-19 Male	20
TX_NEW_DSD	By Age/Sex: 20-24 Male	50
TX_NEW_DSD	By Age/Sex: 25-49 Male	491
TX_NEW_DSD	By Age/Sex: 50+ Male	176
TX_NEW_DSD	By Age/Sex: 10-14 Female	37
TX_NEW_DSD	By Age/Sex: 15-19 Female	32
TX_NEW_DSD	By Age/Sex: 20-24 Female	135
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,131
TX_NEW_DSD	By Age/Sex: 50+ Female	203
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,311
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	112
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	714
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	120



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,516
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,462
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,591
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,591
TX_PVLS_DSD	Numerator: Indication: Routine	7,556
TX_PVLS_DSD	Numerator: Indication: Targeted	3,235
TX_PVLS_DSD	Denominator: Indication: Routine	7,556
TX_PVLS_DSD	Denominator: Indication: Targeted	3,035
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	574
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,212
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	594
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	6,211
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	574
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,212
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	594
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	6,211
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,222
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,222
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	133
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults	32



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	447
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	154
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	33
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	121
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,021
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	198
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and	133



	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	447
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	153
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	29



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	121
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,021
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	198
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	99
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	648
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,368
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	648
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	107
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,368

### Implementing Mechanism Details

<b>Mechanism ID: 13588</b>	<b>Mechanism Name: APHIAplus Nyanza/Western</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 16,870,495</b>	
<b>Applied Pipeline Amount: 12,124,150</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 28,994,645</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	16,870,495

### Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention



Sub Area:	Collection and Use of Gender-related Strategic Information
-----------	--

**Budget Code Information**

<b>Mechanism ID:</b> 13588			
<b>Mechanism Name:</b> APHIAplus Nyanza/Western			
<b>Prime Partner Name:</b> Program for Appropriate Technology in Health			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	3,167,321	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	5,123,141	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	477,816	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	845,170	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,982,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	2,274,147	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	163,919
PMTCT_ART_DSD	New on ART	4,846
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,299
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	163,919
PMTCT_STAT_DSD	Number of new ANC and L&D clients	163,919
PMTCT_STAT_DSD	By: Known positives at entry	4,297
PMTCT_STAT_DSD	By: Number of new positives identified	4,848
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	9,145
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	265
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	413





	new positives: 20-24	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	116
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	320
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	101
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	1,884
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	3,711
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	4,089
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	244
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	697
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	78
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	649
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	55
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	101
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	1,884
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	3,712
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	4,090
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	242
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	44,618
VMMC_CIRC_DSD	By Age: 0-60 days	0



VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	26,761
VMMC_CIRC_DSD	By Age: 15-19	2,681
VMMC_CIRC_DSD	By Age: 20-24	1,787
VMMC_CIRC_DSD	By Age: 25-29	13,389
VMMC_CIRC_DSD	By Age: 30-49	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	31,229
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	44,618
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	44,618
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	6,232
PrEP_NEW_DSD	Female 15-19	1,187
PrEP_NEW_DSD	Female 20-24	5,045
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	81,566
PP_PREV_DSD	Total number of people in the target population	93,317
PP_PREV_DSD	Aggregated Age/sex: <15 Male	59
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	6,028
PP_PREV_DSD	Aggregated Age/sex: <15 Female	7,087
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	68,392
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,101,239
HTC_TST_DSD	Age/sex: 10-14 Male	3,313
HTC_TST_DSD	Age/sex: 15-19 Male	7,267
HTC_TST_DSD	Age/sex: 20-24 Male	9,318
HTC_TST_DSD	Age/sex: 25-49 Male	35,508
HTC_TST_DSD	Age/sex: 50+ Male	9,200
HTC_TST_DSD	Age/sex: 10-14 Female	3,319



HTC_TST_DSD	Age/sex: 15-19 Female	9,748
HTC_TST_DSD	Age/sex: 20-24 Female	24,273
HTC_TST_DSD	Age/sex: 25-49 Female	61,650
HTC_TST_DSD	Age/sex: 50+ Female	14,407
HTC_TST_DSD	Sum of Age/Sex disaggregates	178,003
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	158
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	351
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	459
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,718
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	452
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	159
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	457
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,147
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,991
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	691
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	65,641
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	300,035
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	61,175
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	674,388
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	126,816
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	974,423
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,101,239
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2,305
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	9,481
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,176
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	21,634



	Female	
HTC_TST_DSD	Test Result by Age: Positive: <1	305
HTC_TST_DSD	Test Result by Age: Positive: 1-9	1,549
HTC_TST_DSD	Age/sex: <1	6,602
HTC_TST_DSD	Age/sex: 1-9	33,134
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	108,462
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	268,125
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	108,462
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	17,067
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	147,131
HTC_TST_DSD	Service Delivery Point (Facility): VCT	154,896
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	12,624
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	159,676
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	16,337
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	108,459
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7,309
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	7,309
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	273
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,186
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	553
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,297
GEND_GBV_DSD	Number of people receiving post-GBV care	18,310
GEND_GBV_DSD	Age/Sex: <10 Male	135



GEND_GBV_DSD	Age/Sex: 10-14 Male	232
GEND_GBV_DSD	Age/Sex: 20-24 Male	438
GEND_GBV_DSD	Age/Sex: 25-49 Male	605
GEND_GBV_DSD	Age/Sex: 50+ Male	67
GEND_GBV_DSD	Age/Sex: <10 Female	519
GEND_GBV_DSD	Age/Sex: 10-14 Female	2,899
GEND_GBV_DSD	Age/Sex: 20-24 Female	5,912
GEND_GBV_DSD	Age/Sex: 25-49 Female	1,391
GEND_GBV_DSD	Age/Sex: 50+ Female	154
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	3,785
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	12,259
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,051
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	6,051
GEND_GBV_DSD	Age/Sex: 15-19 Female	5,746
GEND_GBV_DSD	Age/Sex: 15-19 male	212
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	287,783
OVC_SERV_DSD	Age/Sex: 18+ Male	16,938
OVC_SERV_DSD	Age/Sex: 18+ Female	15,371
OVC_SERV_DSD	Sum of Age/Sex disaggregates	32,309
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,405
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	10,084
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,552
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	4,230
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	9,306



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	3,103
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	3,107
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	4,228
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	7,751
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	4,654
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	119,356
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	136,118
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,564
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,564
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	56
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	741
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	163
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,604
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB	120,374

	symptoms at the last clinical visit at a HIV facility during the reporting period.	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	6,785
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	32,260
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6,459
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	74,870
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	8,436
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,666
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,669
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	4,251
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	746
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,197
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	4,243
PMTCT_EID_DSD	Sum of Infant Age disaggregates	9,440
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	163
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	277
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	120,374
TX_CURR_DSD	Age/Sex: 15-19 Male	466
TX_CURR_DSD	Age/Sex: 15-19 Female	912
TX_CURR_DSD	Sum of age/sex disaggregates	1,378
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,781
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	32,265
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,459
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	74,869



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	13,240
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	107,134
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	120,374
TX_CURR_DSD	Age/Sex: <1	79
TX_CURR_DSD	Age/Sex: <1-9	1,392
TX_CURR_DSD	Age/Sex: 10-14 Male	282
TX_CURR_DSD	Age/Sex: 10-14 Female	390
TX_CURR_DSD	Age/Sex: 20-24 Male	594
TX_CURR_DSD	Age/Sex: 25-49 Male	4,639
TX_CURR_DSD	Age/Sex: 50+ Male	1,167
TX_CURR_DSD	Age/Sex: 20-24 Female	2,366
TX_CURR_DSD	Age/Sex: 25-49 Female	11,474
TX_CURR_DSD	Age/Sex: 50+ Female	2,011
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	38,511
TX_NEW_DSD	By Age/Sex: <1	90
TX_NEW_DSD	By Age/Sex: 1-9	724
TX_NEW_DSD	By Age/Sex: 10-14 Male	115
TX_NEW_DSD	By Age/Sex: 15-19 Male	109
TX_NEW_DSD	By Age/Sex: 20-24 Male	116
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,756
TX_NEW_DSD	By Age/Sex: 50+ Male	398
TX_NEW_DSD	By Age/Sex: 10-14 Female	134
TX_NEW_DSD	By Age/Sex: 15-19 Female	175
TX_NEW_DSD	By Age/Sex: 20-24 Female	737
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,810
TX_NEW_DSD	By Age/Sex: 50+ Female	607
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,957
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,727
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	9,532
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,433
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	25,819





TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	38,511
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	108,340
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	120,374
TX_PVLS_DSD	Numerator: Indication: Routine	98,590
TX_PVLS_DSD	Numerator: Indication: Targeted	9,750
TX_PVLS_DSD	Denominator: Indication: Routine	109,536
TX_PVLS_DSD	Denominator: Indication: Targeted	10,838
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	6,120
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	29,027
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	5,811
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	67,382
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	6,781
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	32,265
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	6,459
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	74,869
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	34,840
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	38,511
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	83
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	667
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	108



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	101
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,609
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	358
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	125
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	159
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	681
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,429
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	560
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	724



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,751
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	389
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	175



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	741
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,821
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	607
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,563
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,625
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,285
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23,367
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,727
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	9,532



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,433
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25,819

**Implementing Mechanism Details**

<b>Mechanism ID: 13636</b>	<b>Mechanism Name: APHIAplus Central/Eastern</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 8,690,200</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,690,200</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	8,690,200

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 13636			
<b>Mechanism Name:</b> APHIAplus Central/Eastern			
<b>Prime Partner Name:</b> JHPIEGO			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,348,628	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	2,488,367	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	432,954	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	174,663	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	472,902	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	732,052	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,523,079	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	PDX	517,555	0
-----------	-----	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	74,789
PMTCT_ART_DSD	New on ART	749
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	597
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,384
PMTCT_ART_TA	New on ART	49
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	36
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	74,789
PMTCT_STAT_DSD	Number of new ANC and L&D clients	74,789
PMTCT_STAT_DSD	By: Known positives at entry	673
PMTCT_STAT_DSD	By: Number of new positives identified	727
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,400
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,384
PMTCT_STAT_TA	Number of new ANC and L&D clients	7,384
PMTCT_STAT_TA	By: Known positives at entry	38
PMTCT_STAT_TA	By: Number of new positives identified	54
PMTCT_STAT_TA	Sum of Positives Status disaggregates	92
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	111,756



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,305
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	44,330
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,600
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	52,521
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	14,905
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	96,851
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	111,756
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	172
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	808
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	186
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	952
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	72,894
HTC_TST_DSD	Service Delivery Point (Facility): VCT	32,949
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	5,913
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	134,600
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,631
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	55,490
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,961
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	65,516
HTC_TST_TA	Sum of Aggregated Age/Sex <15	13,592





HTC_TST_TA	Sum of Aggregated Age/Sex 15+	121,006
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	134,598
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	81
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,073
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	118
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,259
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	87,655
HTC_TST_TA	Service Delivery Point (Facility): VCT	40,016
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	6,930
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,503
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,995
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	297
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,133
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	250
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,828
GEND_GBV_DSD	Number of people receiving post-GBV care	1,250
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,250
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,044
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR	113,108



	OVC programs for children and families affected by HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 18+ Male	3,057
OVC_SERV_DSD	Age/Sex: 18+ Female	3,171
OVC_SERV_DSD	Sum of Age/Sex disaggregates	6,228
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	52,930
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	53,950
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,466
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,466
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	81
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	717
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	600
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	38,648
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,196
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	14,311

TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,385
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	19,756
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,867
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,867
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,867
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	882
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	312
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,194
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	12
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	46
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	7
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	2
PMTCT_EID_TA	Sum of Infant Age disaggregates	9
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	38,648
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,189
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,315
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,374



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	19,770
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,563
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	34,085
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	38,648
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,233
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	235
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,078
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	278
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,642
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,233
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	34,785
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	38,820
TX_PVLS_DSD	Numerator: Indication: Routine	27,823
TX_PVLS_DSD	Numerator: Indication: Targeted	6,962
TX_PVLS_DSD	Denominator: Indication: Routine	31,059
TX_PVLS_DSD	Denominator: Indication: Targeted	7,761
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,965
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	13,496
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,142
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	17,182
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,219
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	14,205
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,639
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	19,757
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,721
TX_RET_DSD	Total number of adults and children who initiated ART	5,846



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	232
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,842
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	269
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,378
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	284
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,303
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	327
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,932



**Implementing Mechanism Details**

<b>Mechanism ID: 13701</b>	<b>Mechanism Name: KEMSA Medical Commodities Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Kenya Medical Supplies Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 143,391,701</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 143,391,701</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	143,391,701

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13701		
<b>Mechanism Name:</b>	KEMSA Medical Commodities Program		
<b>Prime Partner Name:</b>	Kenya Medical Supplies Agency		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	2,855,772	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	1,643,640	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	PDCS	320,944	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	2,013,586	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	850,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	8,017,024	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,729,612	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	92,000,001	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	24,148,487	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	9,612,635	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
INVS_COMD	Number of HIV Test Kits purchased	8,699,516
INVS_COMD	Number of HIV CD4 Reagents purchased	264,533
INVS_COMD	Number of HIV Viral Load Reagents purchased	1,395,681
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	1,395,477
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	2,536,871

### Implementing Mechanism Details

<b>Mechanism ID: 13802</b>	<b>Mechanism Name: Central Province Response Integration, Strengthening &amp; Sustainability Project (CRISSP)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>13802</b>
----------------------	--------------





<b>Mechanism Name:</b> Central Province Response Integration, Strengthening & Sustainability			
<b>Prime Partner Name:</b> Project (CRISSP)			
University of Nairobi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13868</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



**Implementing Mechanism Details**

<b>Mechanism ID: 13882</b>	<b>Mechanism Name: Integrated Program for both HIV infected and affected children and their households</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Children of God Relief Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,647,637</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,647,637</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,647,637

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13882		
<b>Mechanism Name:</b>	Integrated Program for both HIV infected and affected children and their households		
<b>Prime Partner Name:</b>	Children of God Relief Institute		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	11,317	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	595,562	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	19,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	461,810	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	16,792	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	328,639	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	213,929	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	New on ART	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,843
HTC_TST_DSD	Age/sex: 10-14 Male	251
HTC_TST_DSD	Age/sex: 15-19 Male	363
HTC_TST_DSD	Age/sex: 20-24 Male	844
HTC_TST_DSD	Age/sex: 25-49 Male	839
HTC_TST_DSD	Age/sex: 50+ Male	93
HTC_TST_DSD	Age/sex: 10-14 Female	272
HTC_TST_DSD	Age/sex: 15-19 Female	387
HTC_TST_DSD	Age/sex: 20-24 Female	905
HTC_TST_DSD	Age/sex: 25-49 Female	940



HTC_TST_DSD	Age/sex: 50+ Female	94
HTC_TST_DSD	Sum of Age/Sex disaggregates	4,988
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	77
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	36
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	44
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	29
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	9
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	82
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	40
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	45
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	30
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	10
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	692
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,137
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	693
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,321
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,385
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	4,458
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,843
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	156
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	117
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	175
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	128
HTC_TST_DSD	Test Result by Age: Positive: <1	30
HTC_TST_DSD	Test Result by Age: Positive: 1-9	88



HTC_TST_DSD	Age/sex: <1	165
HTC_TST_DSD	Age/sex: 1-9	411
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	5,843
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	76
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	76
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	26
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	29
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,586
OVC_SERV_DSD	Age/Sex: 18+ Male	1,229
OVC_SERV_DSD	Age/Sex: 18+ Female	1,829



OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,058
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,728
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,800
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	26
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	26
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,387
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,120
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	539
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,134
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	594
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	39
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent:	37

	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	36
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	40
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	61
PMTCT_EID_DSD	Sum of Infant Age disaggregates	101
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	26
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,387
TX_CURR_DSD	Age/Sex: 15-19 Male	441
TX_CURR_DSD	Age/Sex: 15-19 Female	473
TX_CURR_DSD	Sum of age/sex disaggregates	914
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,120
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	539
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,134
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	594
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,254
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,133
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,387
TX_CURR_DSD	Age/Sex: <1	96
TX_CURR_DSD	Age/Sex: <1-9	879
TX_CURR_DSD	Age/Sex: 10-14 Male	595
TX_CURR_DSD	Age/Sex: 10-14 Female	607
TX_CURR_DSD	Age/Sex: 20-24 Male	93



TX_CURR_DSD	Age/Sex: 25-49 Male	0
TX_CURR_DSD	Age/Sex: 50+ Male	0
TX_CURR_DSD	Age/Sex: 20-24 Female	96
TX_CURR_DSD	Age/Sex: 25-49 Female	0
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	360
TX_NEW_DSD	By Age/Sex: <1	11
TX_NEW_DSD	By Age/Sex: 1-9	116
TX_NEW_DSD	By Age/Sex: 10-14 Male	73
TX_NEW_DSD	By Age/Sex: 15-19 Male	40
TX_NEW_DSD	By Age/Sex: 20-24 Male	0
TX_NEW_DSD	By Age/Sex: 25-49 Male	0
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	82
TX_NEW_DSD	By Age/Sex: 15-19 Female	37
TX_NEW_DSD	By Age/Sex: 20-24 Female	1
TX_NEW_DSD	By Age/Sex: 25-49 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	233
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	136
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	37
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	149
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	38
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	360
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,048
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,383
TX_PVLS_DSD	Numerator: Indication: Routine	0





TX_PVLS_DSD	Numerator: Indication: Targeted	3,048
TX_PVLS_DSD	Denominator: Indication: Routine	0
TX_PVLS_DSD	Denominator: Indication: Targeted	3,383
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,021
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	467
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,048
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	512
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,124
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	533
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,144
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	582
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	324
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	329
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	69
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	33
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



	months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of	34



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	0



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	115
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	120
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	47
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	121



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	47
------------	---	----

**Implementing Mechanism Details**

<b>Mechanism ID: 13919</b>	<b>Mechanism Name: Laboratory Regulatory Support</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 380,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 380,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	380,000

**Cross-Cutting Budget Attribution(s)**

Renovation	100,000
------------	---------

**Budget Code Information**

<b>Mechanism ID: 13919</b>			
<b>Mechanism Name: Laboratory Regulatory Support</b>			
<b>Prime Partner Name: Clinical and Laboratory Standards Institute</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HLAB	380,000	0
------------------------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	10
LAB_PT_TA	CD4: Number of laboratories that perform this testing	10
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	3
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	3
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	10
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	10
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	3
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	3
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of	8



	laboratories that achieve acceptable successful passing criteria in this PT program	
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	10
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	10
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	5
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	6
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	6

**Implementing Mechanism Details**

<b>Mechanism ID: 14009</b>	<b>Mechanism Name: Kenya Nutrition and HIV Program Plus</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,250,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,250,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID: 14009</b>			
<b>Mechanism Name: Kenya Nutrition and HIV Program Plus</b>			
<b>Prime Partner Name: FHI 360</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	400,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14012</b>	<b>Mechanism Name: AMPATHplus</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Moi Teaching and Referral Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 15,501,035</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 15,501,035</b>	





Funding Source	Funding Amount
GHP-State	15,501,035

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	73,448
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

**Budget Code Information**

<b>Mechanism ID: 14012</b>			
<b>Mechanism Name: AMPATHplus</b>			
<b>Prime Partner Name: Moi Teaching and Referral Hospital</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,918,797	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	933,680	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	954,436	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	480,408	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Prevention	HVAB	0	0
Prevention	HVCT	1,558,786	0
Prevention	HVOP	0	0
Prevention	MTCT	1,662,898	0
Treatment	HTXS	6,081,752	0
Treatment	PDTX	610,278	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	127,474
PMTCT_ART_DSD	New on ART	2,109
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,305
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	127,474



PMTCT_STAT_DSD	Number of new ANC and L&D clients	134,183
PMTCT_STAT_DSD	By: Known positives at entry	2,206
PMTCT_STAT_DSD	By: Number of new positives identified	1,812
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,018
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	31
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	31
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	12
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	243
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	243
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	242
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	122
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	31
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	16
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	5



PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	11
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	230
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	230
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	233
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	115
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	702,334
HTC_TST_DSD	Age/sex: 10-14 Male	815
HTC_TST_DSD	Age/sex: 15-19 Male	350
HTC_TST_DSD	Age/sex: 20-24 Male	153
HTC_TST_DSD	Age/sex: 25-49 Male	5,218
HTC_TST_DSD	Age/sex: 50+ Male	2,884
HTC_TST_DSD	Age/sex: 10-14 Female	929
HTC_TST_DSD	Age/sex: 15-19 Female	336
HTC_TST_DSD	Age/sex: 20-24 Female	419
HTC_TST_DSD	Age/sex: 25-49 Female	10,973
HTC_TST_DSD	Age/sex: 50+ Female	2,922
HTC_TST_DSD	Sum of Age/Sex disaggregates	24,999
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	15
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	12
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	5
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	172
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	92
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	17
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	11
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	13
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	357
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	97
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	79,586
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	186,242



	ONLY: 15+ Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	78,519
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	357,186
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	158,105
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	543,428
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	701,533
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	886
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,797
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,034
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	7,290
HTC_TST_DSD	Test Result by Age: Positive: <1	1
HTC_TST_DSD	Test Result by Age: Positive: 1-9	32
HTC_TST_DSD	Age/sex: <1	70
HTC_TST_DSD	Age/sex: 1-9	1,745
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	35,193
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	305,094
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,920
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	3
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	91,582
HTC_TST_DSD	Service Delivery Point (Facility): VCT	141,527
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	124,943
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	774
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,286

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,496
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,207
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,368
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,215
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,864
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	12,422
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	15,286
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	8
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	153
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	12
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	260
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	981
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	7,765
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	105
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	2,576
HTC_TST_TA	Service Delivery Point (Facility): VCT	3,840
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	0
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	19
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,391
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6,614



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	317
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,578
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	202
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,294
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	21,220
OVC_SERV_DSD	Age/Sex: 18+ Male	1,074
OVC_SERV_DSD	Age/Sex: 18+ Female	1,048
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,122
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	9,647
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	9,451
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,425
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,608
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	93
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	1,094

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	110
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,128
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	87,457
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3,917
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	35,125
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,851
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	43,564
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	240
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	48
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	48
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,015
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,075
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,090
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	54
PMTCT_EID_DSD	Number of infants with a positive virological test result	113





	within 12 months of birth	
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	22
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	9
PMTCT_EID_TA	Sum of Infant Age disaggregates	31
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	88,033
TX_CURR_DSD	Age/Sex: 15-19 Male	133
TX_CURR_DSD	Age/Sex: 15-19 Female	128
TX_CURR_DSD	Sum of age/sex disaggregates	261
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,952
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	35,385
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,887
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	43,809
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	8,839
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	79,194
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	88,033
TX_CURR_DSD	Age/Sex: <1	23
TX_CURR_DSD	Age/Sex: <1-9	584
TX_CURR_DSD	Age/Sex: 10-14 Male	273
TX_CURR_DSD	Age/Sex: 10-14 Female	312
TX_CURR_DSD	Age/Sex: 20-24 Male	60
TX_CURR_DSD	Age/Sex: 25-49 Male	1,988
TX_CURR_DSD	Age/Sex: 50+ Male	1,096
TX_CURR_DSD	Age/Sex: 20-24 Female	161
TX_CURR_DSD	Age/Sex: 25-49 Female	4,169
TX_CURR_DSD	Age/Sex: 50+ Female	1,115



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	17,807
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	119
TX_NEW_DSD	By Age/Sex: 10-14 Male	57
TX_NEW_DSD	By Age/Sex: 15-19 Male	27
TX_NEW_DSD	By Age/Sex: 20-24 Male	11
TX_NEW_DSD	By Age/Sex: 25-49 Male	409
TX_NEW_DSD	By Age/Sex: 50+ Male	225
TX_NEW_DSD	By Age/Sex: 10-14 Female	64
TX_NEW_DSD	By Age/Sex: 15-19 Female	26
TX_NEW_DSD	By Age/Sex: 20-24 Female	32
TX_NEW_DSD	By Age/Sex: 25-49 Female	857
TX_NEW_DSD	By Age/Sex: 50+ Female	228
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,936
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	856
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,232
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	985
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	8,778
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	17,851
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	79,231
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	88,035
TX_PVLS_DSD	Numerator: Indication: Routine	68,294
TX_PVLS_DSD	Numerator: Indication: Targeted	11,338
TX_PVLS_DSD	Denominator: Indication: Routine	76,307
TX_PVLS_DSD	Denominator: Indication: Targeted	12,172
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,547
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	31,805



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4,404
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	39,475
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,949
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	35,392
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	4,893
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	43,801
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,622
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	17,805
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	366
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults	57



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	772
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	206
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	121
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	61
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of	12



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	397
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	231
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	855
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months	228



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	663
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,923
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	812
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,224
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	819
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,235
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	987
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,764



**Implementing Mechanism Details**

<b>Mechanism ID: 14015</b>	<b>Mechanism Name: FUNZO Kenya</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,662,500</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,662,500</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,662,500

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 14015</b>			
<b>Mechanism Name: FUNZO Kenya</b>			
<b>Prime Partner Name: IntraHealth International, Inc</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	862,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	2,975
HRH_PRE	By Graduates: Nurses	1,389
HRH_PRE	By Graduates: Laboratory professionals	179





HRH_PRE	By Graduates: Other	1,407
HRH_PRE	Sum of Graduates disaggreagtes	2,975

### Implementing Mechanism Details

<b>Mechanism ID: 14022</b>	<b>Mechanism Name: APHIAplus Imarisha</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,170,219</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,170,219</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,170,219

### Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

### Budget Code Information

<b>Mechanism ID:</b>	14022		
<b>Mechanism Name:</b>	APHIAplus Imarisha		
<b>Prime Partner Name:</b>	African Medical and Research Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	334,858	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	629,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	110,290	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	59,348	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	331,435	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	361,135	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	140,720	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	371,102	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	708,253	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	123,578	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,526
PMTCT_ART_DSD	New on ART	326
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	180
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	77,849
PMTCT_ART_TA	New on ART	317
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	143
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	17,526
PMTCT_STAT_DSD	Number of new ANC and L&D clients	18,449
PMTCT_STAT_DSD	By: Known positives at entry	176
PMTCT_STAT_DSD	By: Number of new positives identified	288
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	464
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	77,849
PMTCT_STAT_TA	Number of new ANC and L&D clients	81,946
PMTCT_STAT_TA	By: Known positives at entry	192
PMTCT_STAT_TA	By: Number of new positives identified	992
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,184
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,580
VMMC_CIRC_DSD	By Age: 2 months - 9 years	277
VMMC_CIRC_DSD	By Age: 10-14	1,475
VMMC_CIRC_DSD	By Age: 15-19	2,988
VMMC_CIRC_DSD	By Age: 20-24	1,363
VMMC_CIRC_DSD	By Age: 25-29	304



VMMC_CIRC_DSD	By Age: 30-49	173
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	5,826
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	6,303
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,580
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,518
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,518
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	95,425
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,331
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	26,391
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,375
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	56,328
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	12,706
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	82,719
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	95,425
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	65
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	670
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	70
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	660



	Female	
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,666
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	44,622
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	12,400
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	6,458
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	29,092
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,187
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	142,517
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,309
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,327
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,013
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	114,868
HTC_TST_TA	Sum of Aggregated Age/Sex <15	4,322
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	138,195
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	142,517
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	87
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,255
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	59
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	836



HTC_TST_TA	Service Delivery Point (Facility): Inpatient	3,612
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	16,477
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	4
HTC_TST_TA	Service Delivery Point (Facility): VCT	29,722
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	91,672
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,030
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	165
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	174
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	149
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,967
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,071
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of	452



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	38
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,426
GEND_GBVDSD	Number of people receiving post-GBV care	3
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	3
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	3
GEND_GBVT_A	Number of people receiving post-GBV care	14
GEND_GBVT_A	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBVT_A	By type of service: Sexual Violence (Post-Rape Care)	14
GEND_GBVT_A	By PEP service provision (related to sexual violence services provided)	14
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	19,728
OVC_SERV_DSD	Age/Sex: 18+ Male	719
OVC_SERV_DSD	Age/Sex: 18+ Female	668
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,387
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	9,459
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	8,882
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	66
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	69
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with	0



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	46
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	185
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	195
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	62
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	114





	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,739
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	255
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,807
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	246
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,431
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	50
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	50
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	50
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,259
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	377
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	1,712
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	354
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	3,808
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	170
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	170
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	170
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	156
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	435
PMTCT_EID_DSD	Sum of Infant Age disaggregates	591
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	161
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	113
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	278
PMTCT_EID_TA	Sum of Infant Age disaggregates	391
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	25
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,739
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	243
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,885
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	258
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,353
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	501
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,238
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	5,739
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	6,259
TX_CURR_TA	Aggregated Age/Sex: <15 Male	375
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,711
TX_CURR_TA	Aggregated Age/Sex: <15 Female	356
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,817



TX_CURR_TA	Sum of Aggregated Age/Sex <15	731
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	5,528
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	6,259
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,512
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	28
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	313
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	18
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	555
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	914
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,410
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	50
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	549
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	39
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	772
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,410
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,165
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,739
TX_PVLS_DSD	Numerator: Indication: Routine	4,219
TX_PVLS_DSD	Numerator: Indication: Targeted	946
TX_PVLS_DSD	Denominator: Indication: Routine	4,694
TX_PVLS_DSD	Denominator: Indication: Targeted	1,045
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	232
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,641



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	228
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	3,067
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	249
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,805
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	255
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	3,430
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,633
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,259
TX_PVLS_TA	Numerator: Indication: Routine	4,612
TX_PVLS_TA	Numerator: Indication: Targeted	1,022
TX_PVLS_TA	Denominator: Indication: Routine	5,124
TX_PVLS_TA	Denominator: Indication: Targeted	1,135
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	330
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,576
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	312
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	3,415
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	366
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,707
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	348
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	3,837
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,817
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,512
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment	54



	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	700
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,023
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	322
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	957
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	56
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,177
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,030
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	1,438



	stopped ART, and those lost to follow-up	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	347
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	629
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	148
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	495
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	46
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	749

**Implementing Mechanism Details**

<b>Mechanism ID: 14034</b>	<b>Mechanism Name: The OVC Scholarship and</b>
----------------------------	--

Approved



	<b>Leadership Program</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14034		
<b>Mechanism Name:</b>	The OVC Scholarship and Leadership Program		
<b>Prime Partner Name:</b>	Equity Group Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16450</b>	<b>Mechanism Name: Global Give Back Circle</b>
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Community Development Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 380,386</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 380,386</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	380,386

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16450</b>			
<b>Mechanism Name: Global Give Back Circle</b>			
<b>Prime Partner Name: Kenya Community Development Foundation</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	380,386	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16670</b>	<b>Mechanism Name: HIV Fellowship Program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement





Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,050,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,050,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,050,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,050,000
----------------------------	-----------

**Budget Code Information**

<b>Mechanism ID: 16670</b>			
<b>Mechanism Name: HIV Fellowship Program</b>			
<b>Prime Partner Name: University of Nairobi</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	850,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	12
HRH_PRE	By Graduates: Doctors	6
HRH_PRE	By Graduates: Nurses	1
HRH_PRE	By Graduates: Midwives	0
HRH_PRE	By Graduates: Social service workers	1
HRH_PRE	By Graduates: Laboratory professionals	0
HRH_PRE	By Graduates: Other	4
HRH_PRE	Sum of Graduates disaggreagtes	12

### Implementing Mechanism Details

<b>Mechanism ID: 16679</b>	<b>Mechanism Name: Program Support Services</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: International Business & Technical Consultants Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 16679			
<b>Mechanism Name:</b> Program Support Services			
<b>Prime Partner Name:</b> International Business & Technical Consultants Inc.			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 16684	<b>Mechanism Name:</b> Kenya Disciplined Services ZUIA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,129,322</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,129,322</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,129,322

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	270,000
Gender: GBV	33,750
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	67,500
Gender: Gender Equality	33,750
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information

**Budget Code Information**

<b>Mechanism ID: 16684</b>			
<b>Mechanism Name: Kenya Disciplined Services ZUIA</b>			
<b>Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	70,729	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	22,269	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	13,207	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	190,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	63,862	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	525,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	57,974	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	166,471	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	19,810	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,433
PMTCT_ART_DSD	New on ART	77
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	203
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,433
PMTCT_STAT_DSD	Number of new ANC and L&D clients	14,433
PMTCT_STAT_DSD	By: Known positives at entry	65
PMTCT_STAT_DSD	By: Number of new positives identified	179
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	244
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	0



	new positives: 15-19	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	12
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	19
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	100
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	647
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	1,379
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	48
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	14
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	19
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	100
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	647
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	1,379
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	90,000



	minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	90,000
PP_PREV_DSD	Aggregated Age/sex: <15 Male	2,428
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	43,039
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,959
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	41,574
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	78,046
HTC_TST_DSD	Age/sex: 10-14 Male	158
HTC_TST_DSD	Age/sex: 15-19 Male	1,570
HTC_TST_DSD	Age/sex: 20-24 Male	3,846
HTC_TST_DSD	Age/sex: 25-49 Male	7,843
HTC_TST_DSD	Age/sex: 50+ Male	838
HTC_TST_DSD	Age/sex: 10-14 Female	175
HTC_TST_DSD	Age/sex: 15-19 Female	2,147
HTC_TST_DSD	Age/sex: 20-24 Female	5,203
HTC_TST_DSD	Age/sex: 25-49 Female	10,791
HTC_TST_DSD	Age/sex: 50+ Female	1,072
HTC_TST_DSD	Sum of Age/Sex disaggregates	33,643
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	9
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	40
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	105
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	224
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	23
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	17
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	78
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	175
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	384
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	34
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	918





HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	34,836
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,125
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	41,167
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,043
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	76,003
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	78,046
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	41
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	596
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	67
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,116
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	32
HTC_TST_DSD	Age/sex: <1	21
HTC_TST_DSD	Age/sex: 1-9	565
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	52,676
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	21,458
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	3,095
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	111
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	706
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,455



TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,455
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	753
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	636
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	114
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	114
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	45



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,709
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	77
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	710
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	81
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,841
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	542
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	489
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	489
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	145
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	83
PMTCT_EID_DSD	Sum of Infant Age disaggregates	228
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	4
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,709
TX_CURR_DSD	Age/Sex: 15-19 Male	11
TX_CURR_DSD	Age/Sex: 15-19 Female	38
TX_CURR_DSD	Sum of age/sex disaggregates	49
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	77
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	710



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	81
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,841
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	158
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,551
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,709
TX_CURR_DSD	Age/Sex: <1	11
TX_CURR_DSD	Age/Sex: <1-9	102
TX_CURR_DSD	Age/Sex: 10-14 Male	23
TX_CURR_DSD	Age/Sex: 10-14 Female	22
TX_CURR_DSD	Age/Sex: 20-24 Male	35
TX_CURR_DSD	Age/Sex: 25-49 Male	494
TX_CURR_DSD	Age/Sex: 50+ Male	170
TX_CURR_DSD	Age/Sex: 20-24 Female	164
TX_CURR_DSD	Age/Sex: 25-49 Female	1,369
TX_CURR_DSD	Age/Sex: 50+ Female	270
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,605
TX_NEW_DSD	By Age/Sex: <1	21
TX_NEW_DSD	By Age/Sex: 1-9	45
TX_NEW_DSD	By Age/Sex: 10-14 Male	10
TX_NEW_DSD	By Age/Sex: 15-19 Male	2
TX_NEW_DSD	By Age/Sex: 20-24 Male	34
TX_NEW_DSD	By Age/Sex: 25-49 Male	348
TX_NEW_DSD	By Age/Sex: 50+ Male	96
TX_NEW_DSD	By Age/Sex: 10-14 Female	11
TX_NEW_DSD	By Age/Sex: 15-19 Female	7
TX_NEW_DSD	By Age/Sex: 20-24 Female	138
TX_NEW_DSD	By Age/Sex: 25-49 Female	750
TX_NEW_DSD	By Age/Sex: 50+ Female	143
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,539
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	49
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	480



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	38
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,038
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,605
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,455
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,455
TX_PVLS_DSD	Numerator: Indication: Routine	2,455
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	75
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	640
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	78
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,662
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	75
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	640
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	78
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,662
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,441
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,605
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	10



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	313
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	88
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	121
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	668
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	128
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	45



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	347
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	7

	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	750
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	143
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	48
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	434
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	922
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	480





	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,038

**Implementing Mechanism Details**

<b>Mechanism ID: 16687</b>	<b>Mechanism Name: Kenya Prison Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Strat Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,593,199</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,593,199</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,593,199

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	308,303
Gender: GBV	3,854
Focus Area:	Post GBV Care



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Gender: Gender Equality	3,854
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID:</b> 16687			
<b>Mechanism Name:</b> Kenya Prison Services			
<b>Prime Partner Name:</b> Health Strat Kenya			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	196,030	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	111,720	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	36,604	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	160,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	141,865	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	378,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	102,688	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	411,387	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	54,905	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,776
PMTCT_ART_DSD	New on ART	92
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	263
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,776
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,776
PMTCT_STAT_DSD	By: Known positives at entry	240
PMTCT_STAT_DSD	By: Number of new positives identified	86
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	326
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	0



	new positives: 15-19	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	9
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	20
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	103
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	663
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	1,414
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	60
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	12
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	19
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	4
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	20
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	103
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	663
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	1,414
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	54,000



	minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	54,000
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	31,516
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	22,484
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	106,769
HTC_TST_DSD	Age/sex: 10-14 Male	1,221
HTC_TST_DSD	Age/sex: 15-19 Male	7,424
HTC_TST_DSD	Age/sex: 20-24 Male	24,363
HTC_TST_DSD	Age/sex: 25-49 Male	29,581
HTC_TST_DSD	Age/sex: 50+ Male	6,136
HTC_TST_DSD	Age/sex: 10-14 Female	728
HTC_TST_DSD	Age/sex: 15-19 Female	3,259
HTC_TST_DSD	Age/sex: 20-24 Female	12,858
HTC_TST_DSD	Age/sex: 25-49 Female	16,257
HTC_TST_DSD	Age/sex: 50+ Female	3,195
HTC_TST_DSD	Sum of Age/Sex disaggregates	105,022
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	23
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	130
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	495
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	579
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	102
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	13
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	89
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	327
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	381
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	76
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,530



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	68,555
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	886
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	35,798
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,416
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	104,353
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	106,769
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	55
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,749
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	44
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,820
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	47
HTC_TST_DSD	Age/sex: 1-9	413
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	5,995
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	64,576
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,038
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	791
HTC_TST_DSD	Service Delivery Point (Facility): VCT	25,856
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	845
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	5,994
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	222
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,452
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,309



TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,309
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	113
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	600
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	85
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	511
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	390
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	390
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	53
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	172
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	128



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,368
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	100
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	3,389
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	102
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,777
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,275
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,152
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,152
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	187
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	75
PMTCT_EID_DSD	Sum of Infant Age disaggregates	262
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	12
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,368
TX_CURR_DSD	Age/Sex: 15-19 Male	84
TX_CURR_DSD	Age/Sex: 15-19 Female	68
TX_CURR_DSD	Sum of age/sex disaggregates	152
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	100
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,389





TX_CURR_DSD	Aggregated Age/Sex: <15 Female	102
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,777
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	202
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,166
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,368
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	141
TX_CURR_DSD	Age/Sex: 10-14 Male	29
TX_CURR_DSD	Age/Sex: 10-14 Female	32
TX_CURR_DSD	Age/Sex: 20-24 Male	167
TX_CURR_DSD	Age/Sex: 25-49 Male	2,346
TX_CURR_DSD	Age/Sex: 50+ Male	792
TX_CURR_DSD	Age/Sex: 20-24 Female	242
TX_CURR_DSD	Age/Sex: 25-49 Female	2,057
TX_CURR_DSD	Age/Sex: 50+ Female	410
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,314
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	37
TX_NEW_DSD	By Age/Sex: 10-14 Male	21
TX_NEW_DSD	By Age/Sex: 15-19 Male	12
TX_NEW_DSD	By Age/Sex: 20-24 Male	59
TX_NEW_DSD	By Age/Sex: 25-49 Male	804
TX_NEW_DSD	By Age/Sex: 50+ Male	262
TX_NEW_DSD	By Age/Sex: 10-14 Female	27
TX_NEW_DSD	By Age/Sex: 15-19 Female	14
TX_NEW_DSD	By Age/Sex: 20-24 Female	87
TX_NEW_DSD	By Age/Sex: 25-49 Female	803
TX_NEW_DSD	By Age/Sex: 50+ Female	183
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,272
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	44
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,136



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	47
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,087
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,314
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,749
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,749
TX_PVLS_DSD	Numerator: Indication: Routine	5,749
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	5,749
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	95
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,054
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	96
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,504
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	95
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,054
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	95
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	2,504
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,083
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,314
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37



TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	730
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	236
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	79
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	710
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	162
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5



TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	61
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	803
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	261
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of	13



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	88
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	803
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	183
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,030
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	964
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	44



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,136
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	47
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,087

### Implementing Mechanism Details

<b>Mechanism ID: 16705</b>	<b>Mechanism Name: IDU - HIV Combination Prevention</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,402,765</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,402,765</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,402,765

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 16705			
<b>Mechanism Name:</b> IDU - HIV Combination Prevention			
<b>Prime Partner Name:</b> United Nations Office on Drug and Crime (UNODC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	1,402,765	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	4,589
KP_MAT_DSD	Sex: Male	3,381
KP_MAT_DSD	Sex: Female	1,208
KP_MAT_DSD	Sum of Sex disaggregates	4,589
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,247
KP_PREV_DSD	Total estimated number of key population in the catchment area	8,507
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,176
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations	1,089



	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	7,134
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	1,516

**Implementing Mechanism Details**

<b>Mechanism ID: 16709</b>	<b>Mechanism Name: Accelerating Progress Against TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,500,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16709
----------------------------





<b>Mechanism Name:</b> Accelerating Progress Against TB			
<b>Prime Partner Name:</b> Center for Health Solutions (CHS)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,500,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16710</b>	<b>Mechanism Name: Expanding Health Insurance Coverage</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
Funding Source	Funding Amount
GHP-State	200,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 16710
----------------------------



<b>Mechanism Name:</b> Expanding Health Insurance Coverage			
<b>Prime Partner Name:</b> Equity Group Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17190	<b>Mechanism Name:</b> Wezesha Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Life Skills Promoters	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 968,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 968,000	
Funding Source	Funding Amount
GHP-State	968,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17190
----------------------------



<b>Mechanism Name:</b>	<b>Wezesha Project</b>		
<b>Prime Partner Name:</b>	<b>Life Skills Promoters</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	968,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,000
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	9,676
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	12,324

### Implementing Mechanism Details

<b>Mechanism ID: 17191</b>	<b>Mechanism Name: Watoto Wazima Initiative)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Reformed Church of East Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 228,492</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 228,492</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	228,492

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	17191		
<b>Mechanism Name:</b>	Watoto Wazima Initiative)		
<b>Prime Partner Name:</b>	Reformed Church of East Africa		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	228,492	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	5,193
OVC_SERV_DSD	Age/Sex: 18+ Male	79
OVC_SERV_DSD	Age/Sex: 18+ Female	62
OVC_SERV_DSD	Sum of Age/Sex disaggregates	141
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,581
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,471

### Implementing Mechanism Details

<b>Mechanism ID: 17707</b>	<b>Mechanism Name: Nilinde Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: PLAN International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 6,515,991</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,515,991</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,515,991

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17707</b>			
<b>Mechanism Name: Nilinde Project</b>			
<b>Prime Partner Name: PLAN International</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	6,515,991	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	148,967
OVC_SERV_DSD	Age/Sex: 18+ Male	7,755
OVC_SERV_DSD	Age/Sex: 18+ Female	8,346
OVC_SERV_DSD	Sum of Age/Sex disaggregates	16,101
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	64,746
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	68,120



**Implementing Mechanism Details**

<b>Mechanism ID: 17709</b>	<b>Mechanism Name: HRH Kenya</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,157,500</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,157,500</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,157,500

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17709</b>			
<b>Mechanism Name: HRH Kenya</b>			
<b>Prime Partner Name: IntraHealth International, Inc</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	2,457,500	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17711</b>	<b>Mechanism Name: Implementation and expansion of blood safety</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Blood Transfusion Service, Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Approved



<b>Total All Funding Sources: 850,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 850,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	850,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	270,000
Renovation	156,000
Motor Vehicles: Purchased	160,000

### Budget Code Information

<b>Mechanism ID:</b>	17711		
<b>Mechanism Name:</b>	Implementation and expansion of blood safety		
<b>Prime Partner Name:</b>	National Blood Transfusion Service, Kenya		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	850,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17712	<b>Mechanism Name:</b> Strengthening Strategic Information in Kenya
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted



Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,550,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,550,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,550,000

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	93,000
---------------------------	--------

**Budget Code Information**

<b>Mechanism ID:</b>	17712		
<b>Mechanism Name:</b>	Strengthening Strategic Information in Kenya		
<b>Prime Partner Name:</b>	University of California at San Francisco		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	3,300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	250,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17718</b>	<b>Mechanism Name: Afya Jijini</b>
----------------------------	------------------------------------



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Interchurch Medical Assistance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 8,134,682</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,134,682</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	8,134,682

**Cross-Cutting Budget Attribution(s)**

Water	10,000
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

**Budget Code Information**

<b>Mechanism ID: 17718</b>			
<b>Mechanism Name: Afya Jijini</b>			
<b>Prime Partner Name: Interchurch Medical Assistance</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,561,098	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	675,070	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	211,304	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	37,827	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	786,906	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	561,382	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	708,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,495,895	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	96,439	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	53,076
PMTCT_ART_DSD	New on ART	616
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	915



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	53,076
PMTCT_STAT_DSD	Number of new ANC and L&D clients	53,076
PMTCT_STAT_DSD	By: Known positives at entry	1,062
PMTCT_STAT_DSD	By: Number of new positives identified	456
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,518
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	527
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	531
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	113
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	6,271
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	18,992
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	16,621
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	11,079
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	459
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	113
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	6,271
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	18,992
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	16,621
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	11,079
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention	751



	program within the reporting period	
VMMC_CIRC_DSD	By Age: 0-60 days	5
VMMC_CIRC_DSD	By Age: 2 months - 9 years	23
VMMC_CIRC_DSD	By Age: 10-14	300
VMMC_CIRC_DSD	By Age: 15-19	225
VMMC_CIRC_DSD	By Age: 20-24	113
VMMC_CIRC_DSD	By Age: 25-29	45
VMMC_CIRC_DSD	By Age: 30-49	27
VMMC_CIRC_DSD	By Age: 50+	13
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	651
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	723
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	751
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	603
PrEP_NEW_DSD	Female 15-19	115
PrEP_NEW_DSD	Female 20-24	488
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	221,151
HTC_TST_DSD	Age/sex: 10-14 Male	700
HTC_TST_DSD	Age/sex: 15-19 Male	12,384
HTC_TST_DSD	Age/sex: 20-24 Male	24,751
HTC_TST_DSD	Age/sex: 25-49 Male	28,886
HTC_TST_DSD	Age/sex: 50+ Male	16,508
HTC_TST_DSD	Age/sex: 10-14 Female	1,338
HTC_TST_DSD	Age/sex: 15-19 Female	21,017
HTC_TST_DSD	Age/sex: 20-24 Female	40,830
HTC_TST_DSD	Age/sex: 25-49 Female	46,208
HTC_TST_DSD	Age/sex: 50+ Female	26,424
HTC_TST_DSD	Sum of Age/Sex disaggregates	219,046
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	99
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	707



HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,397
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,672
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	944
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	101
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	707
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,399
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,684
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	938
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,754
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	82,731
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,445
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	134,221
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,199
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	216,952
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	221,151
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	360
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,610
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	366
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,597
HTC_TST_DSD	Test Result by Age: Positive: <1	121
HTC_TST_DSD	Test Result by Age: Positive: 1-9	164
HTC_TST_DSD	Age/sex: <1	874
HTC_TST_DSD	Age/sex: 1-9	1,231
HTC_TST_DSD	Service Delivery Point (Community): Other	3,044
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	33,404



HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	49,818
HTC_TST_DSD	Service Delivery Point (Facility): VCT	61,936
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	2,746
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	50,796
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	19,318
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	89
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,850
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6,850
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	173
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,252
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	173
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,252
GEND_GBV_DSD	Number of people receiving post-GBV care	1,141
GEND_GBV_DSD	Age/Sex: 10-14 Female	240
GEND_GBV_DSD	Age/Sex: 20-24 Female	450
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	240
GEND_GBV_DSD	Age/Sex: 15-19 Female	450
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,680
OVC_SERV_DSD	Age/Sex: 18+ Female	405
OVC_SERV_DSD	Sum of Age/Sex disaggregates	405
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	160



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	977
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	153
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	143
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	653
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	722
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	330
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,133
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	330
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	333
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	797
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,353
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,353
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,107
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,020
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB	3,020





	treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	76
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,434
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	76
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,434
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	41,904
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,074
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	19,878
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,074
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	19,878
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,520
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	267
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,787
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	46
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	25
TX_CURR_DSD	Number of adults and children receiving antiretroviral	43,716



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	4,045
TX_CURR_DSD	Age/Sex: 15-19 Female	4,045
TX_CURR_DSD	Sum of age/sex disaggregates	8,090
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,615
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	20,243
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,615
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	20,243
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,230
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	40,486
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	43,716
TX_CURR_DSD	Age/Sex: <1	330
TX_CURR_DSD	Age/Sex: <1-9	778
TX_CURR_DSD	Age/Sex: 10-14 Male	1,053
TX_CURR_DSD	Age/Sex: 10-14 Female	1,053
TX_CURR_DSD	Age/Sex: 20-24 Male	5,068
TX_CURR_DSD	Age/Sex: 25-49 Male	6,080
TX_CURR_DSD	Age/Sex: 50+ Male	5,058
TX_CURR_DSD	Age/Sex: 20-24 Female	5,068
TX_CURR_DSD	Age/Sex: 25-49 Female	6,080
TX_CURR_DSD	Age/Sex: 50+ Female	5,058
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,068
TX_NEW_DSD	By Age/Sex: <1	46
TX_NEW_DSD	By Age/Sex: 1-9	68
TX_NEW_DSD	By Age/Sex: 10-14 Male	106
TX_NEW_DSD	By Age/Sex: 15-19 Male	870
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,095
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,318
TX_NEW_DSD	By Age/Sex: 50+ Male	1,099
TX_NEW_DSD	By Age/Sex: 10-14 Female	106
TX_NEW_DSD	By Age/Sex: 15-19 Female	870



TX_NEW_DSD	By Age/Sex: 20-24 Female	1,076
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,318
TX_NEW_DSD	By Age/Sex: 50+ Female	1,096
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,954
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	169
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,374
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	169
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,356
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,068
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	39,344
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	39,344
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,023
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	18,649
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,023
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	18,649
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,023
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	18,649
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,023
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	18,649
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,162
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,162
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81



TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	165
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	214
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	747
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	940
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,107
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	950
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	214
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	747
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	940
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,107
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	950
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	81



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	165
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	214
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	747
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	940
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,107
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	950
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	214



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	747
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	940
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,107
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	950
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	338
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,743
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	338
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,743
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total	338



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,743
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	338
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,743

### Implementing Mechanism Details

<b>Mechanism ID: 17719</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 17944</b>	<b>Mechanism Name: Linkages</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,635,491</b>	
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 3,635,491</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,635,491

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17944</b>			
<b>Mechanism Name: Linkages</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	3,435,491	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	61,511
KP_PREV_DSD	Total estimated number of key population in the catchment area	168,906
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key	6,977





	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	54,534
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	23,280
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	145,636

**Implementing Mechanism Details**

<b>Mechanism ID: 17945</b>	<b>Mechanism Name: mHealth</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: mHealth Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 780,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 780,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	780,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 17945			
<b>Mechanism Name:</b> mHealth			
<b>Prime Partner Name:</b> mHealth Kenya			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	780,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17947	<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 1,175,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,175,000	
Funding Source	Funding Amount
GHP-State	1,175,000

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	179,286
Renovation	50,000
Focus Area:	Post GBV Care



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID:</b>	17947		
<b>Mechanism Name:</b>	Implementation of Sustainable Laboratory Quality Systems		
<b>Prime Partner Name:</b>	African Medical and Research Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	900,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	95,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	180,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
------------------	-------	------



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	14
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	42
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	53
LAB_PT_TA	CD4: Number of laboratories that perform this testing	53
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	54
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	67
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	67
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	54
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	67
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of	67



	laboratories that perform this testing	
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	18
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	23
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	23

**Implementing Mechanism Details**

<b>Mechanism ID: 17948</b>	<b>Mechanism Name: Laboratory Networking</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17948
<b>Mechanism Name:</b>	Laboratory Networking
<b>Prime Partner Name:</b>	African Society for Laboratory Medicine



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17950</b>	<b>Mechanism Name: Implementation of Sustainable Laboratory Quality Systems</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,520,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,520,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,520,000

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	90,000
Renovation	150,000

**Budget Code Information**



<b>Mechanism ID:</b> 17950			
<b>Mechanism Name:</b> Implementation of Sustainable Laboratory Quality Systems			
<b>Prime Partner Name:</b> University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	2,900,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	355,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	385,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	560,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	61
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	76
LAB_PT_TA	CD4: Number of laboratories that perform this testing	76
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
LAB_PT_TA	Early infant diagnostics: Number of laboratories that	7



	participate in this PT program	
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	7
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	89
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	108
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	108
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	7
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	7
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	89
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	108
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	108
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	29
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	36
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	36
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1





LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1

**Implementing Mechanism Details**

<b>Mechanism ID: 17951</b>	<b>Mechanism Name: Implementation of Sustainable Laboratory Quality Systems</b>		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: FHI 360			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

<b>Total All Funding Sources: 1,224,573</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,224,573</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,224,573

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	93,700
Renovation	70,000

**Budget Code Information**

<b>Mechanism ID:</b>	17951		
<b>Mechanism Name:</b>	Implementation of Sustainable Laboratory Quality Systems		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HLAB	924,573	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	120,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	180,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	75
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	75
LAB_PT_TA	CD4: Number of laboratories that perform this testing	75
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	67
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	67
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	67
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT	0



	program	
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	67
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	67
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	67
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	31
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	31
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	31
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0

### Implementing Mechanism Details

<b>Mechanism ID: 17954</b>	<b>Mechanism Name: Implementation of Sustainable Laboratory Quality Systems</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Implementation Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 3,100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,100,000

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	120,000
Renovation	100,000

**Budget Code Information**

<b>Mechanism ID:</b>	17954		
<b>Mechanism Name:</b>	Implementation of Sustainable Laboratory Quality Systems		
<b>Prime Partner Name:</b>	Global Implementation Solutions		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	2,325,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	625,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	73
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	91
LAB_PT_TA	CD4: Number of laboratories that perform this testing	91
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	184
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	231
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	231
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	HIV viral load: Number of laboratories that participate in this PT program	0
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	0
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	184
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	231
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	231



LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	19
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	24
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	24
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0

**Implementing Mechanism Details**

<b>Mechanism ID: 17956</b>	<b>Mechanism Name: VMMC QA Support</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 180,036</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 180,036</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	180,036

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17956			
<b>Mechanism Name:</b> VMCC QA Support			
<b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	180,036	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17958	<b>Mechanism Name:</b> Afyainfo National Mechanism Follow on (HIGDA)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 2,850,000	
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 2,850,000	
Funding Source	Funding Amount
GHP-State	2,850,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 17958			
<b>Mechanism Name:</b> Afyainfo National Mechanism Follow on (HIGDA)			
<b>Prime Partner Name:</b> Palladium Group			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	2,850,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	501
PMTCT_ART_DSD	New on ART	48
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	134
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	501
PMTCT_STAT_DSD	Number of new ANC and L&D clients	502
PMTCT_STAT_DSD	By: Known positives at entry	81
PMTCT_STAT_DSD	By: Number of new positives identified	28
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	109
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	21
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	12
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	18
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	76





	known positives: <15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	25
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	56
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	25
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	151
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	322
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	5
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	99
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	28
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	81
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	4
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	95
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	42
PMTCT_EID_DSD	Sum of Infant Age disaggregates	137
PMTCT_EID_DSD	Number of infants with a positive virological test result	5



	within 2 months of birth	
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	4

### Implementing Mechanism Details

<b>Mechanism ID: 17959</b>	<b>Mechanism Name: Sustaining National HMIS Kenya</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,500,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17959		
<b>Mechanism Name:</b>	Sustaining National HMIS Kenya		
<b>Prime Partner Name:</b>	University of Nairobi		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	1,500,000	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17960</b>	<b>Mechanism Name: Avenir Health</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	200,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17960		
<b>Mechanism Name:</b>	Avenir Health		
<b>Prime Partner Name:</b>	Population Council		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	200,000	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17964</b>	<b>Mechanism Name: Measure Evaluation IV</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 250,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17964		
<b>Mechanism Name:</b>	Measure Evaluation IV		
<b>Prime Partner Name:</b>	University of North Carolina		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	50,000	0
------------------------	------	--------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18203</b>	<b>Mechanism Name: EGPAF Timiza</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 16,960,431</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 16,960,431</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	16,960,431

### Cross-Cutting Budget Attribution(s)

Gender: GBV	1,438,877
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	1,438,877
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID: 18203</b>			
<b>Mechanism Name: EGPAF Timiza</b>			
<b>Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	2,144,316	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	274,461	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	643,649	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	381,725	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HLAB	70,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,764,880	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,055,998	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,419,257	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	8,603,558	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	572,587	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	157,958
PMTCT_ART_DSD	New on ART	6,828
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	19,385
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	157,958
PMTCT_STAT_DSD	Number of new ANC and L&D clients	157,958
PMTCT_STAT_DSD	By: Known positives at entry	12,883



PMTCT_STAT_DSD	By: Number of new positives identified	4,911
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	17,794
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	18
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	466
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	128
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	1,249
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	634
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	3,373
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	21,748
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	46,003
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	55
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	7,006
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	1,219
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	2,470
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	441
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	649
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	3,367





PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	21,647
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	45,987
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	171
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	139,568
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	83,385
VMMC_CIRC_DSD	By Age: 15-19	40,770
VMMC_CIRC_DSD	By Age: 20-24	7,006
VMMC_CIRC_DSD	By Age: 25-29	4,028
VMMC_CIRC_DSD	By Age: 30-49	3,509
VMMC_CIRC_DSD	By Age: 50+	356
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	131,517
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	139,054
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	135,167
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	4,000
PrEP_NEW_DSD	Male 15-19	0
PrEP_NEW_DSD	Male 20-24	0
PrEP_NEW_DSD	Male 25-49	0
PrEP_NEW_DSD	Male 50+	0
PrEP_NEW_DSD	Female 15-19	0
PrEP_NEW_DSD	Female 20-24	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
PP_PREV_DSD	Total number of people in the target population	0
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	0
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	0



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,901,126
HTC_TST_DSD	Age/sex: 10-14 Male	115,547
HTC_TST_DSD	Age/sex: 15-19 Male	129,467
HTC_TST_DSD	Age/sex: 20-24 Male	216,005
HTC_TST_DSD	Age/sex: 25-49 Male	362,383
HTC_TST_DSD	Age/sex: 50+ Male	78,686
HTC_TST_DSD	Age/sex: 10-14 Female	110,019
HTC_TST_DSD	Age/sex: 15-19 Female	146,338
HTC_TST_DSD	Age/sex: 20-24 Female	306,538
HTC_TST_DSD	Age/sex: 25-49 Female	526,646
HTC_TST_DSD	Age/sex: 50+ Female	100,693
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,092,322
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	1,137
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	2,691
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	6,643
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	11,444
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	2,627
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	1,522
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	3,871
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	9,744
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	17,249
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	3,824
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	409,936
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	826,245
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	480,366
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,172,615
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	890,302



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,998,860
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,889,162
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	5,533
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	31,397
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	7,754
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	49,128
HTC_TST_DSD	Test Result by Age: Positive: <1	9
HTC_TST_DSD	Test Result by Age: Positive: 1-9	8,250
HTC_TST_DSD	Age/sex: <1	14,977
HTC_TST_DSD	Age/sex: 1-9	622,900
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	169,863
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	1,717,359
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	30,713
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	50
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	23,190
HTC_TST_DSD	Service Delivery Point (Facility): VCT	701,187
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	33,248
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	169,078
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	6,683
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	42,317
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	8,832
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	8,832
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	278
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	4,559



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	191
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,792
GEND_GBV_DSD	Number of people receiving post-GBV care	0
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,952
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,952
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	159
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,240
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	116
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,562
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during	324,584



	the reporting period.	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	15,036
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	93,275
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	16,396
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	201,108
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	64,986
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	58,455
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	58,454
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	23
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	18,056
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	5,916
PMTCT_EID_DSD	Sum of Infant Age disaggregates	23,972
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	765
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	787
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	324,584
TX_CURR_DSD	Age/Sex: 15-19 Male	2,838
TX_CURR_DSD	Age/Sex: 15-19 Female	4,933
TX_CURR_DSD	Sum of age/sex disaggregates	7,771
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	14,914
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	93,163
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	16,344
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	200,346
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	31,258



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	293,509
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	324,767
TX_CURR_DSD	Age/Sex: <1	612
TX_CURR_DSD	Age/Sex: <1-9	20,577
TX_CURR_DSD	Age/Sex: 10-14 Male	4,805
TX_CURR_DSD	Age/Sex: 10-14 Female	5,267
TX_CURR_DSD	Age/Sex: 20-24 Male	4,496
TX_CURR_DSD	Age/Sex: 25-49 Male	63,959
TX_CURR_DSD	Age/Sex: 50+ Male	21,597
TX_CURR_DSD	Age/Sex: 20-24 Female	17,598
TX_CURR_DSD	Age/Sex: 25-49 Female	148,569
TX_CURR_DSD	Age/Sex: 50+ Female	29,333
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	95,804
TX_NEW_DSD	By Age/Sex: <1	718
TX_NEW_DSD	By Age/Sex: 1-9	5,212
TX_NEW_DSD	By Age/Sex: 10-14 Male	1,192
TX_NEW_DSD	By Age/Sex: 15-19 Male	497
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,808
TX_NEW_DSD	By Age/Sex: 25-49 Male	19,242
TX_NEW_DSD	By Age/Sex: 50+ Male	6,033
TX_NEW_DSD	By Age/Sex: 10-14 Female	1,372
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,493
TX_NEW_DSD	By Age/Sex: 20-24 Female	6,596
TX_NEW_DSD	By Age/Sex: 25-49 Female	43,683
TX_NEW_DSD	By Age/Sex: 50+ Female	7,940
TX_NEW_DSD	Sum of Age/Sex disaggregates	89,856
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	4,125
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	27,538
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4,369
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	59,712
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	95,744



TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	292,187
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	292,394
TX_PVLS_DSD	Numerator: Indication: Routine	292,178
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	289,182
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	13,748
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	83,712
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	14,820
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	180,477
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	13,548
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	83,712
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	14,819
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	180,478
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	87,245
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	95,722
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	703
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,860
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,121



TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	465
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,748
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,471
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,498
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,279
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,387
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,986
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	39,626
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,227
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	723
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who	5,191





	have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,190
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	507
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,843
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,205
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,005
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,370
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	1,488



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,574
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	43,714
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,913
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,858
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,094
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,144
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	54,185
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,114
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	27,560



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,360
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59,689

**Implementing Mechanism Details**

<b>Mechanism ID: 18204</b>	<b>Mechanism Name: UON CRISSP Plus</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,285,296</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,285,296</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,285,296

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	199,990
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	199,990
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID:</b>	18204		
<b>Mechanism Name:</b>	UON CRISSP Plus		
<b>Prime Partner Name:</b>	University of Nairobi		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	887,636	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	185,016	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	159,726	0
Prevention	HVCT	266,081	0
Prevention	MTCT	489,153	0
Treatment	HTXS	933,094	0
Treatment	PDTX	364,590	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	64,605
PMTCT_ART_DSD	New on ART	288
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	769
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	64,605
PMTCT_STAT_DSD	Number of new ANC and L&D clients	64,605
PMTCT_STAT_DSD	By: Known positives at entry	1,663
PMTCT_STAT_DSD	By: Number of new positives identified	592
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,255
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	0



	new positives: 15-19	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	17
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	86
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	553
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	1,181
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	16
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	6
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	1
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	17
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	86
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	553
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	1,181
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6	0



	months	
KP_MAT_DSD	Sex: Male	0
KP_MAT_DSD	Sex: Female	0
KP_MAT_DSD	Sum of Sex disaggregates	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0
KP_PREV_DSD	Total estimated number of key population in the catchment area	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Females who inject drugs	0





	(Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	325,624
HTC_TST_DSD	Age/sex: 10-14 Male	7,123
HTC_TST_DSD	Age/sex: 15-19 Male	10,941
HTC_TST_DSD	Age/sex: 20-24 Male	27,871
HTC_TST_DSD	Age/sex: 25-49 Male	61,540
HTC_TST_DSD	Age/sex: 50+ Male	10,816
HTC_TST_DSD	Age/sex: 10-14 Female	7,518
HTC_TST_DSD	Age/sex: 15-19 Female	11,373
HTC_TST_DSD	Age/sex: 20-24 Female	34,030
HTC_TST_DSD	Age/sex: 25-49 Female	63,087
HTC_TST_DSD	Age/sex: 50+ Female	11,191
HTC_TST_DSD	Sum of Age/Sex disaggregates	245,490
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17,685
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	132,679



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	20,110
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	155,148
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	37,795
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	287,827
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	325,622
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	196
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,908
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	207
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,017
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	878
HTC_TST_DSD	Age/sex: 1-9	16,276
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	15,640
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	207,071
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,706
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,079
HTC_TST_DSD	Service Delivery Point (Facility): VCT	78,733
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	15,645
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	576
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	3,789
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,018
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,018



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	171
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,558
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	134
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,155
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	954
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	954
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	520
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	426
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB	44,604

	symptoms at the last clinical visit at a HIV facility during the reporting period.	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,508
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	13,914
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	3,168
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	24,914
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	8,923
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	8,036
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	8,012
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	726
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	288
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,014
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	23
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	19
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	44,604
TX_CURR_DSD	Age/Sex: 15-19 Male	2,251
TX_CURR_DSD	Age/Sex: 15-19 Female	456
TX_CURR_DSD	Sum of age/sex disaggregates	2,707
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,508
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,914
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,168
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	24,808



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,676
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	38,722
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	44,398
TX_CURR_DSD	Age/Sex: <1	815
TX_CURR_DSD	Age/Sex: <1-9	3,447
TX_CURR_DSD	Age/Sex: 10-14 Male	723
TX_CURR_DSD	Age/Sex: 10-14 Female	691
TX_CURR_DSD	Age/Sex: 20-24 Male	584
TX_CURR_DSD	Age/Sex: 25-49 Male	8,297
TX_CURR_DSD	Age/Sex: 50+ Male	2,800
TX_CURR_DSD	Age/Sex: 20-24 Female	2,212
TX_CURR_DSD	Age/Sex: 25-49 Female	18,661
TX_CURR_DSD	Age/Sex: 50+ Female	3,685
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,543
TX_NEW_DSD	By Age/Sex: <1	30
TX_NEW_DSD	By Age/Sex: 1-9	206
TX_NEW_DSD	By Age/Sex: 10-14 Male	84
TX_NEW_DSD	By Age/Sex: 15-19 Male	22
TX_NEW_DSD	By Age/Sex: 20-24 Male	323
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,208
TX_NEW_DSD	By Age/Sex: 50+ Male	359
TX_NEW_DSD	By Age/Sex: 10-14 Female	96
TX_NEW_DSD	By Age/Sex: 15-19 Female	185
TX_NEW_DSD	By Age/Sex: 20-24 Female	376
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,034
TX_NEW_DSD	By Age/Sex: 50+ Female	620
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,307
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	186
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,922
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	232
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,235



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,575
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	40,226
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	35,702
TX_PVLS_DSD	Numerator: Indication: Routine	40,226
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	29,546
TX_PVLS_DSD	Denominator: Indication: Targeted	164
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,280
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	12,536
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,882
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	22,528
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,620
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	12,445
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,857
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	22,019
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,897
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,543
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	194
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	83



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	294
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,096
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	330
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	92
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	172
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	346
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,692
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	565
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	206



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	323
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,208
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	359
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	185



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	376
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,034
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	620
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	176
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,742
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	218
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,692
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	186
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	1,912



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	230
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,215

### Implementing Mechanism Details

<b>Mechanism ID: 18205</b>	<b>Mechanism Name: UMB PACT Kamili</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,223,928</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,223,928</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,223,928

### Cross-Cutting Budget Attribution(s)

Gender: GBV	377,418
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	377,418
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	18205		
<b>Mechanism Name:</b>	UMB PACT Kamili		
<b>Prime Partner Name:</b>	University of Maryland Baltimore		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,075,877	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	244,284	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	PDCS	342,937	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	645,600	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,082,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	837,483	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	350,342	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,287,410	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	357,995	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	118,093
PMTCT_ART_DSD	New on ART	941
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,681
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	118,093
PMTCT_STAT_DSD	Number of new ANC and L&D clients	118,093



PMTCT_STAT_DSD	By: Known positives at entry	3,493
PMTCT_STAT_DSD	By: Number of new positives identified	1,444
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,937
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	66
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	24
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	199
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	256
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	1,371
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	8,875
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	18,867
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,151
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	230
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	393
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	75
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	254



PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	1,381
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	8,880
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	18,898
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	8,777
PrEP_NEW_DSD	Female 15-19	1,655
PrEP_NEW_DSD	Female 20-24	7,169
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,989
PP_PREV_DSD	Total number of people in the target population	59,911
PP_PREV_DSD	Aggregated Age/sex: <15 Male	986
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	186
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,777
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	6,473
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	608,965
HTC_TST_DSD	Age/sex: 10-14 Male	14,366
HTC_TST_DSD	Age/sex: 15-19 Male	8,875
HTC_TST_DSD	Age/sex: 20-24 Male	28,775
HTC_TST_DSD	Age/sex: 25-49 Male	60,433
HTC_TST_DSD	Age/sex: 50+ Male	7,590
HTC_TST_DSD	Age/sex: 10-14 Female	22,660
HTC_TST_DSD	Age/sex: 15-19 Female	16,369
HTC_TST_DSD	Age/sex: 20-24 Female	57,388
HTC_TST_DSD	Age/sex: 25-49 Female	125,835
HTC_TST_DSD	Age/sex: 50+ Female	11,548
HTC_TST_DSD	Sum of Age/Sex disaggregates	353,839
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	39
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	91



HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	487
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,880
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	266
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	91
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	241
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,231
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	4,619
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	585
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	85,432
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	116,614
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	154,749
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	251,285
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	240,181
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	367,899
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	608,080
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,089
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	5,782
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,036
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	16,123
HTC_TST_DSD	Test Result by Age: Positive: <1	20
HTC_TST_DSD	Test Result by Age: Positive: 1-9	404
HTC_TST_DSD	Age/sex: <1	610
HTC_TST_DSD	Age/sex: 1-9	131,236
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	36,264
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	369,758



HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	6,417
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	4,921
HTC_TST_DSD	Service Delivery Point (Facility): VCT	141,294
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	2,771
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	36,284
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,367
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	9,031
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	70,858
HTC_TST_TA	Age/sex: 10-14 Male	175
HTC_TST_TA	Age/sex: 15-19 Male	2,593
HTC_TST_TA	Age/sex: 20-24 Male	10,381
HTC_TST_TA	Age/sex: 25-49 Male	26,788
HTC_TST_TA	Age/sex: 50+ Male	1,580
HTC_TST_TA	Age/sex: 10-14 Female	124
HTC_TST_TA	Age/sex: 15-19 Female	1,794
HTC_TST_TA	Age/sex: 20-24 Female	7,197
HTC_TST_TA	Age/sex: 25-49 Female	18,575
HTC_TST_TA	Age/sex: 50+ Female	1,095
HTC_TST_TA	Sum of Age/Sex disaggregates	70,302
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	4
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	17
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	109
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	411
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	32
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	11
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	57
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	328
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	1,108
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	86





HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	95
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,704
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	306
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,534
HTC_TST_TA	Sum of Aggregated Age/Sex <15	401
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	25,238
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	25,639
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	9
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	550
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	25
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,602
HTC_TST_TA	Test Result by Age: Positive: <1	2
HTC_TST_TA	Test Result by Age: Positive: 1-9	16
HTC_TST_TA	Age/sex: <1	46
HTC_TST_TA	Age/sex: 1-9	502
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	4,005
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	41,677
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	693
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	528
HTC_TST_TA	Service Delivery Point (Facility): VCT	17,274
HTC_TST_TA	Service Delivery Point (Facility): VMMC	1,558
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	4,005
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	146
HTC_TST_TA	Service Delivery Point (Facility): Index testing	967



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6,080
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6,080
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	291
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,044
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	175
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,565
GEND_GBV_DSD	Number of people receiving post-GBV care	18,092
GEND_GBV_DSD	Age/Sex: 10-14 Female	2,138
GEND_GBV_DSD	Age/Sex: 20-24 Female	7,957
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	2,138
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	10,973
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	7,119
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,151
GEND_GBV_DSD	Age/Sex: 15-19 Female	7,952
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	15,293
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	10,702
OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,702
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	702
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	3,570
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	587
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	1,044
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	2,738
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	580
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	595
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	595
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	581
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	2,108
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	889
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	1,799



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	1,155
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,056
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,662
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,182
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	10,182
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	10,182
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,591
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	578
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	1,456
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,759
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,759
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	106
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	934
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	35

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	681
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	87,882
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3,921
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	23,211
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,059
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	56,367
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	17,581
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	15,536
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	15,836
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	24
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,164
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	968
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,132
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	54
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	94
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	87,882
TX_CURR_DSD	Age/Sex: 15-19 Male	527



TX_CURR_DSD	Age/Sex: 15-19 Female	1,262
TX_CURR_DSD	Sum of age/sex disaggregates	1,789
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,913
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	23,250
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,061
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	56,656
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,974
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	79,906
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	87,880
TX_CURR_DSD	Age/Sex: <1	102
TX_CURR_DSD	Age/Sex: <1-9	5,259
TX_CURR_DSD	Age/Sex: 10-14 Male	1,308
TX_CURR_DSD	Age/Sex: 10-14 Female	1,307
TX_CURR_DSD	Age/Sex: 20-24 Male	1,127
TX_CURR_DSD	Age/Sex: 25-49 Male	16,138
TX_CURR_DSD	Age/Sex: 50+ Male	5,462
TX_CURR_DSD	Age/Sex: 20-24 Female	4,989
TX_CURR_DSD	Age/Sex: 25-49 Female	41,994
TX_CURR_DSD	Age/Sex: 50+ Female	8,307
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	21,684
TX_NEW_DSD	By Age/Sex: <1	104
TX_NEW_DSD	By Age/Sex: 1-9	772
TX_NEW_DSD	By Age/Sex: 10-14 Male	211
TX_NEW_DSD	By Age/Sex: 15-19 Male	104
TX_NEW_DSD	By Age/Sex: 20-24 Male	448
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,460
TX_NEW_DSD	By Age/Sex: 50+ Male	1,248
TX_NEW_DSD	By Age/Sex: 10-14 Female	253
TX_NEW_DSD	By Age/Sex: 15-19 Female	316
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,610
TX_NEW_DSD	By Age/Sex: 25-49 Female	10,427





TX_NEW_DSD	By Age/Sex: 50+ Female	1,731
TX_NEW_DSD	Sum of Age/Sex disaggregates	20,808
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	632
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	6,161
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	707
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	14,085
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	21,585
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	79,438
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	77,924
TX_PVLS_DSD	Numerator: Indication: Routine	79,111
TX_PVLS_DSD	Numerator: Indication: Targeted	327
TX_PVLS_DSD	Denominator: Indication: Routine	77,898
TX_PVLS_DSD	Denominator: Indication: Targeted	23
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,577
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	20,972
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3,726
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	51,146
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,528
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	20,542
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,651
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	50,237
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	19,319
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	21,684
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children	99



	who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	716
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	198
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	401
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,978
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,125
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	235
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	284
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,449
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,183
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,552



TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	104
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	772
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	211
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	104
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	448
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,464
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,244
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of	253



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	316
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,609
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,428
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,727
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	592
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,603
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	656
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	12,468



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	633
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,259
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	707
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,085

**Implementing Mechanism Details**

<b>Mechanism ID: 18206</b>	<b>Mechanism Name: KCCB KARP</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Conference of Catholic Bishops	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 11,006,593</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 11,006,593</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	11,006,593



**Cross-Cutting Budget Attribution(s)**

Gender: GBV	453,973
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	453,973
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID:</b> 18206			
<b>Mechanism Name:</b> KCCB KARP			
<b>Prime Partner Name:</b> Kenya Conference of Catholic Bishops			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,317,292	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	729,595	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	432,697	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	306,237	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,117,615	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	5,454,112	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	649,045	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,476
PMTCT_ART_DSD	New on ART	1,486
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,239
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,476
PMTCT_STAT_DSD	Number of new ANC and L&D clients	50,476
PMTCT_STAT_DSD	By: Known positives at entry	3,524
PMTCT_STAT_DSD	By: Number of new positives identified	1,284
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,808



PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	7
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	80
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	29
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	221
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	87
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	455
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	2,926
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	6,246
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,277
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	258
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	448
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	90
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	87
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	455
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	2,926
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	6,652





PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	409,773
HTC_TST_DSD	Age/sex: 10-14 Male	7,728
HTC_TST_DSD	Age/sex: 15-19 Male	15,786
HTC_TST_DSD	Age/sex: 20-24 Male	23,926
HTC_TST_DSD	Age/sex: 25-49 Male	52,519
HTC_TST_DSD	Age/sex: 50+ Male	16,050
HTC_TST_DSD	Age/sex: 10-14 Female	9,175
HTC_TST_DSD	Age/sex: 15-19 Female	19,237
HTC_TST_DSD	Age/sex: 20-24 Female	36,428
HTC_TST_DSD	Age/sex: 25-49 Female	104,789
HTC_TST_DSD	Age/sex: 50+ Female	21,718
HTC_TST_DSD	Sum of Age/Sex disaggregates	307,356
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	86
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	185
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	453
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,849
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	257
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	139
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	233
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	754
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,928
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	372
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	32,676
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	112,109
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	45,678
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	219,277



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	78,354
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	331,386
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	409,740
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	735
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,979
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,248
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	8,223
HTC_TST_DSD	Test Result by Age: Positive: <1	209
HTC_TST_DSD	Test Result by Age: Positive: 1-9	700
HTC_TST_DSD	Age/sex: <1	6,525
HTC_TST_DSD	Age/sex: 1-9	49,672
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	23,714
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	244,136
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	4,108
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	3,133
HTC_TST_DSD	Service Delivery Point (Facility): VCT	101,855
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	2,456
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	23,705
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	883
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	5,752
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,735
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,735
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	285
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	2,824



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	228
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,398
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,793
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,793
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,407
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	82
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,184
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	125,752
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,550
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	35,858



TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	5,714
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	77,750
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	25,125
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	22,638
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	22,460
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4,066
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,339
PMTCT_EID_DSD	Sum of Infant Age disaggregates	6,405
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	140
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	144
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	125,752
TX_CURR_DSD	Age/Sex: 15-19 Male	1,450
TX_CURR_DSD	Age/Sex: 15-19 Female	2,001
TX_CURR_DSD	Sum of age/sex disaggregates	3,451
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,611
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	36,091
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,776
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	78,274
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	11,387
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	114,365
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	125,752
TX_CURR_DSD	Age/Sex: <1	112



TX_CURR_DSD	Age/Sex: <1-9	7,098
TX_CURR_DSD	Age/Sex: 10-14 Male	2,092
TX_CURR_DSD	Age/Sex: 10-14 Female	2,085
TX_CURR_DSD	Age/Sex: 20-24 Male	1,732
TX_CURR_DSD	Age/Sex: 25-49 Male	24,592
TX_CURR_DSD	Age/Sex: 50+ Male	8,317
TX_CURR_DSD	Age/Sex: 20-24 Female	6,863
TX_CURR_DSD	Age/Sex: 25-49 Female	57,967
TX_CURR_DSD	Age/Sex: 50+ Female	11,443
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,315
TX_NEW_DSD	By Age/Sex: <1	235
TX_NEW_DSD	By Age/Sex: 1-9	1,747
TX_NEW_DSD	By Age/Sex: 10-14 Male	290
TX_NEW_DSD	By Age/Sex: 15-19 Male	207
TX_NEW_DSD	By Age/Sex: 20-24 Male	427
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,616
TX_NEW_DSD	By Age/Sex: 50+ Male	1,477
TX_NEW_DSD	By Age/Sex: 10-14 Female	410
TX_NEW_DSD	By Age/Sex: 15-19 Female	682
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,139
TX_NEW_DSD	By Age/Sex: 25-49 Female	10,284
TX_NEW_DSD	By Age/Sex: 50+ Female	1,801
TX_NEW_DSD	Sum of Age/Sex disaggregates	23,333
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,355
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	8,290
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,546
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	16,111
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	27,302
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	113,242



	laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	116,838
TX_PVLS_DSD	Numerator: Indication: Routine	112,665
TX_PVLS_DSD	Numerator: Indication: Targeted	612
TX_PVLS_DSD	Denominator: Indication: Routine	106,368
TX_PVLS_DSD	Denominator: Indication: Targeted	4,392
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	5,075
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	32,492
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	5,217
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	70,458
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	5,075
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	32,492
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5,217
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	70,458
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	22,903
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	25,313
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	223
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,605
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	272
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	196



TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	390
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,074
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,345
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	374
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	627
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,942
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,236
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,623
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	235
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,747
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of	290



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	207
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	427
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,638
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,477
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	410
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	682
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	2,139





	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,284
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,801
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,084
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,876
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,295
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,156
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,253
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,727



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,429
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,906

**Implementing Mechanism Details**

<b>Mechanism ID: 18207</b>	<b>Mechanism Name: Columbia STARS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,039,788</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,039,788</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,039,788

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18207</b>
----------------------------



<b>Mechanism Name:</b> Columbia STARS			
<b>Prime Partner Name:</b> Columbia University			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	333,429	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	104,979	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	62,259	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	64,400	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	155,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	252,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	189,555	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	784,777	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	93,389	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
-------------------------	--------------	-------------



PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,958
PMTCT_ART_DSD	New on ART	228
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	649
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,958
PMTCT_STAT_DSD	Number of new ANC and L&D clients	7,958
PMTCT_STAT_DSD	By: Known positives at entry	501
PMTCT_STAT_DSD	By: Number of new positives identified	176
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	677
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	22
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	63
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	71
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	374
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	2,397
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	4,116
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0



PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	358
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	71
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	125
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	25
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	71
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	374
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	2,397
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	5,116
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,926
VMMC_CIRC_DSD	By Age: 10-14	1,286
VMMC_CIRC_DSD	By Age: 15-19	240
VMMC_CIRC_DSD	By Age: 20-24	149
VMMC_CIRC_DSD	By Age: 25-29	108
VMMC_CIRC_DSD	By Age: 30-49	137
VMMC_CIRC_DSD	By Age: 50+	6
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	1,681
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	1,926
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,926
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	65,875
HTC_TST_DSD	Age/sex: 10-14 Male	183
HTC_TST_DSD	Age/sex: 15-19 Male	601
HTC_TST_DSD	Age/sex: 20-24 Male	8,864
HTC_TST_DSD	Age/sex: 25-49 Male	13,830
HTC_TST_DSD	Age/sex: 50+ Male	1,574



HTC_TST_DSD	Age/sex: 10-14 Female	182
HTC_TST_DSD	Age/sex: 15-19 Female	1,257
HTC_TST_DSD	Age/sex: 20-24 Female	10,075
HTC_TST_DSD	Age/sex: 25-49 Female	20,924
HTC_TST_DSD	Age/sex: 50+ Female	6,864
HTC_TST_DSD	Sum of Age/Sex disaggregates	64,354
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	4
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	121
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	704
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	123
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	30
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	208
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,199
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	209
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	771
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,016
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,113
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	40,975
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,884
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	63,991
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	65,875
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	76
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	964
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	91



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,646
HTC_TST_DSD	Test Result by Age: Positive: <1	14
HTC_TST_DSD	Test Result by Age: Positive: 1-9	142
HTC_TST_DSD	Age/sex: <1	200
HTC_TST_DSD	Age/sex: 1-9	1,321
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	8,247
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	35,797
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,428
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,090
HTC_TST_DSD	Service Delivery Point (Facility): VCT	5,554
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	3,209
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	8,247
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	303
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,998
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,111
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,111
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	58
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	541
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	462
TB_ART_DSD	The number of registered new and relapse TB cases	441



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	441
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	223
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	193
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	20,394
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	785
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	6,136
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	761
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	12,712
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	4,079
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,671
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert	3,671



	MTB/RIF assay	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	835
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	109
PMTCT_EID_DSD	Sum of Infant Age disaggregates	944
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	46
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	19
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	20,394
TX_CURR_DSD	Age/Sex: 15-19 Male	479
TX_CURR_DSD	Age/Sex: 15-19 Female	1,161
TX_CURR_DSD	Sum of age/sex disaggregates	1,640
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	785
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,136
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	761
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	12,712
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,546
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	18,848
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	20,394
TX_CURR_DSD	Age/Sex: <1	13
TX_CURR_DSD	Age/Sex: <1-9	1,061
TX_CURR_DSD	Age/Sex: 10-14 Male	249
TX_CURR_DSD	Age/Sex: 10-14 Female	223
TX_CURR_DSD	Age/Sex: 20-24 Male	283
TX_CURR_DSD	Age/Sex: 25-49 Male	4,017
TX_CURR_DSD	Age/Sex: 50+ Male	1,357
TX_CURR_DSD	Age/Sex: 20-24 Female	1,040
TX_CURR_DSD	Age/Sex: 25-49 Female	8,779



TX_CURR_DSD	Age/Sex: 50+ Female	1,732
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,863
TX_NEW_DSD	By Age/Sex: <1	51
TX_NEW_DSD	By Age/Sex: 1-9	198
TX_NEW_DSD	By Age/Sex: 10-14 Male	69
TX_NEW_DSD	By Age/Sex: 15-19 Male	87
TX_NEW_DSD	By Age/Sex: 20-24 Male	110
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,027
TX_NEW_DSD	By Age/Sex: 50+ Male	275
TX_NEW_DSD	By Age/Sex: 10-14 Female	84
TX_NEW_DSD	By Age/Sex: 15-19 Female	212
TX_NEW_DSD	By Age/Sex: 20-24 Female	496
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,869
TX_NEW_DSD	By Age/Sex: 50+ Female	385
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,614
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	198
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,499
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	204
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,962
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,863
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	18,358
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	18,358
TX_PVLS_DSD	Numerator: Indication: Routine	18,358
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	18,367
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	708



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	5,523
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	686
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	11,441
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	708
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,523
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	686
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	11,441
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,378
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,863
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	179
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	79
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	99
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	925
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	247



TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	191
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	446
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,682
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	347
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	198
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	87



TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	110
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,027
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	275
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	212
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	496
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,869
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of	385



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	178
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,350
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	184
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,666
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	198
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,499
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	204
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	2,962



	stopped ART, and those lost to follow-up)	
--	---	--

**Implementing Mechanism Details**

<b>Mechanism ID: 18208</b>	<b>Mechanism Name: IRDO Tuungane 3</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 7,842,084</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 7,842,084</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	7,842,084

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	137,357
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	142,784
Focus Area:	Equity in HIV prevention, care, treatment and support
Human Resources for Health	733,929
Key Populations: MSM and TG	231,302
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and



	operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	693,907
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Economic Strengthening	462,604
Education	103,104
Condom programming	115,651
Condom procurement	115,651

**Budget Code Information**

<b>Mechanism ID:</b>	18208		
<b>Mechanism Name:</b>	IRDO Tuungane 3		
<b>Prime Partner Name:</b>	Impact Research and Development Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Prevention	CIRC	459,628	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	152,513	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	2,687,291	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	2,320,077	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	29,840	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,192,735	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	423
KP_MAT_DSD	Sex: Male	363
KP_MAT_DSD	Sex: Female	60
KP_MAT_DSD	Sum of Sex disaggregates	423
VMMC_CIRC_DSD	By Age: 10-14	682
VMMC_CIRC_DSD	By Age: 15-19	46
VMMC_CIRC_DSD	By Age: 20-24	6
VMMC_CIRC_DSD	By Age: 25-29	4
VMMC_CIRC_DSD	By Age: 30-49	9
VMMC_CIRC_DSD	By Age: 50+	3



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	737
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	750
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	750
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	130,174
PP_PREV_DSD	Total number of people in the target population	186,251
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,470
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	47,539
PP_PREV_DSD	Aggregated Age/sex: <15 Female	637
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	80,352
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	20,793
KP_PREV_DSD	Total estimated number of key population in the catchment area	20,793
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	103
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,804
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	18,152
KP_PREV_DSD	By key population type: Males who inject drugs ( Male	631



	PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	103
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	103
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,804
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	18,152
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	631
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	103
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	147,257
HTC_TST_DSD	Age/sex: 10-14 Male	10,280
HTC_TST_DSD	Age/sex: 15-19 Male	20,209
HTC_TST_DSD	Age/sex: 20-24 Male	10,082
HTC_TST_DSD	Age/sex: 25-49 Male	16,033
HTC_TST_DSD	Age/sex: 50+ Male	2,532
HTC_TST_DSD	Age/sex: 10-14 Female	7,209



HTC_TST_DSD	Age/sex: 15-19 Female	14,159
HTC_TST_DSD	Age/sex: 20-24 Female	8,211
HTC_TST_DSD	Age/sex: 25-49 Female	12,645
HTC_TST_DSD	Age/sex: 50+ Female	1,797
HTC_TST_DSD	Sum of Age/Sex disaggregates	103,157
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	96
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	93
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	161
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	569
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	79
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	46
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	65
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	159
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	529
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	80
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	36,625
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50,692
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,953
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	38,518
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	56,578
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	89,210
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	145,788
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	824
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,543
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	516
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	999



	Female	
HTC_TST_DSD	Test Result by Age: Positive: <1	17
HTC_TST_DSD	Test Result by Age: Positive: 1-9	895
HTC_TST_DSD	Age/sex: <1	345
HTC_TST_DSD	Age/sex: 1-9	34,128
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	8,053
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	84,215
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,396
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,062
HTC_TST_DSD	Service Delivery Point (Facility): VCT	39,911
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	2,708
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	8,054
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	294
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,949
GEND_GBV_DSD	Number of people receiving post-GBV care	3,005
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,754
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	751
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	751
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	44,542
OVC_SERV_DSD	Age/Sex: 18+ Male	303
OVC_SERV_DSD	Age/Sex: 18+ Female	24,956
OVC_SERV_DSD	Sum of Age/Sex disaggregates	25,259
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	2,054
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	10,041



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,656
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	44
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	1,631
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	804
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	9,830
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	917
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	263
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	44
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,631
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	804
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,766
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	3,833
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	2,885
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	44
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	1,631
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	804
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	1,637
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,045
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	3,656
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	9,608
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	44
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,630



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	804
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,637
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	9,070
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	6,027
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	44
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,630
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	804
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	303
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,845
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	1,845
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	1,845
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	1,844





OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	1,844
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,324
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	14,958
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,788
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	1,788
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	1,788
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	1,787
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	1,757
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	48
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	4
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	44
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	10
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	10
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	10
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	48
TX_CURR_DSD	Age/Sex: 15-19 Male	0
TX_CURR_DSD	Age/Sex: 15-19 Female	0



TX_CURR_DSD	Sum of age/sex disaggregates	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	66
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	78
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	78
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	0
TX_CURR_DSD	Age/Sex: 10-14 Male	0
TX_CURR_DSD	Age/Sex: 10-14 Female	0
TX_CURR_DSD	Age/Sex: 20-24 Male	0
TX_CURR_DSD	Age/Sex: 25-49 Male	9
TX_CURR_DSD	Age/Sex: 50+ Male	3
TX_CURR_DSD	Age/Sex: 20-24 Female	7
TX_CURR_DSD	Age/Sex: 25-49 Female	49
TX_CURR_DSD	Age/Sex: 50+ Female	10
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	43
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	39
TX_PVLS_DSD	Numerator: Indication: Routine	43
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	39
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	4
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	39
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	4
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	39

### Implementing Mechanism Details

<b>Mechanism ID: 18209</b>	<b>Mechanism Name: LVCT Daraja</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,319,939</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,319,939</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,319,939

### Cross-Cutting Budget Attribution(s)

Gender: GBV	218,177
Focus Area:	Post GBV Care
Sub Area:	Implementation
Gender: Gender Equality	223,604
Focus Area:	Equity in HIV prevention, care, treatment and support
Human Resources for Health	1,057,209
Key Populations: MSM and TG	392,942
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	1,178,826
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Economic Strengthening	785,884
Education	103,104
Condom programming	196,471
Condom procurement	196,471

**Budget Code Information**

<b>Mechanism ID:</b> 18209
----------------------------



<b>Mechanism Name:</b> LVCT Daraja			
<b>Prime Partner Name:</b> Liverpool VCT and Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	173,013	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	45,157	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	34,164	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	152,487	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	702,452	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,440,352	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	484,097	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	288,217	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	880



PMTCT_ART_DSD	New on ART	9
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	25
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	880
PMTCT_STAT_DSD	Number of new ANC and L&D clients	880
PMTCT_STAT_DSD	By: Known positives at entry	35
PMTCT_STAT_DSD	By: Number of new positives identified	13
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	48
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	41
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	265
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	566
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	25
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	5



	known positives: 50+	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	9
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	2
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	8
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	41
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	265
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	566
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	2,937
KP_MAT_DSD	Sex: Male	2,780
KP_MAT_DSD	Sex: Female	457
KP_MAT_DSD	Sum of Sex disaggregates	3,237
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	12,240
PP_PREV_DSD	Total number of people in the target population	12,292
PP_PREV_DSD	Aggregated Age/sex: <15 Male	246
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	46
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,363
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	8,443
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	69,986
KP_PREV_DSD	Total estimated number of key population in the catchment area	66,244
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	10,790



	evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	52,540
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,641
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,016
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	612
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	10,178
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	50,237
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	1,423
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	3,795
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	107,373





HTC_TST_DSD	Age/sex: 10-14 Male	2,220
HTC_TST_DSD	Age/sex: 15-19 Male	3,977
HTC_TST_DSD	Age/sex: 20-24 Male	11,739
HTC_TST_DSD	Age/sex: 25-49 Male	28,451
HTC_TST_DSD	Age/sex: 50+ Male	4,115
HTC_TST_DSD	Age/sex: 10-14 Female	1,664
HTC_TST_DSD	Age/sex: 15-19 Female	3,080
HTC_TST_DSD	Age/sex: 20-24 Female	9,617
HTC_TST_DSD	Age/sex: 25-49 Female	24,816
HTC_TST_DSD	Age/sex: 50+ Female	3,120
HTC_TST_DSD	Sum of Age/Sex disaggregates	92,799
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	23
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	68
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	340
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	67
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	32
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	84
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	291
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,250
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	250
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,264
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,299
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,215
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	53,277
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	13,479
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	72,576
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	86,055



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	76
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	558
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	133
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,204
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	124
HTC_TST_DSD	Age/sex: <1	50
HTC_TST_DSD	Age/sex: 1-9	11,489
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	4,913
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	51,353
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	848
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	1
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	648
HTC_TST_DSD	Service Delivery Point (Facility): VCT	21,185
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	1,681
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	4,913
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	185
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,193
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	53
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	53
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	28
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	1



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
GEND_GBV_DSD	Number of people receiving post-GBV care	5,863
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,104
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,759
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,814
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,711
OVC_SERV_DSD	Age/Sex: 18+ Male	183
OVC_SERV_DSD	Age/Sex: 18+ Female	11,408
OVC_SERV_DSD	Sum of Age/Sex disaggregates	11,591
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	22
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,765
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	4,594
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	767
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	947
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	468
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	175



	and sex: Education Support Male 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	281
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	4,287
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	534
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	151
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	947
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	462
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	177
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	93
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,167
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,325
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	971
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	22



	and sex: Social Protection Male <1	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	947
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	467
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	176
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	20
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	1,346
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	1,107
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,077
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	3,049
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,377
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,013
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	505
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	166
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	2,728
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	2,361



	and sex: Other Services Female 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	1,268
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	2,219
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1,731
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	1,450
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	1,272
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	1,072
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	1,072
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	1,079
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	1,070
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	1,073
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,571
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	7,449
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	1,071
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	1,043
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	1,260
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	1,115

	and sex: Economic Strengthening Female 1-9	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	1,369
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	39
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	39
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,915
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	9
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	543
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	14
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,349
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	784
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent:	706



	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	706
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	23
PMTCT_EID_DSD	Sum of Infant Age disaggregates	25
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,915
TX_CURR_DSD	Age/Sex: 15-19 Male	5
TX_CURR_DSD	Age/Sex: 15-19 Female	21
TX_CURR_DSD	Sum of age/sex disaggregates	26
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	9
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	543
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	14
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,349
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	23
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,892
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,915
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	15
TX_CURR_DSD	Age/Sex: 10-14 Male	4
TX_CURR_DSD	Age/Sex: 10-14 Female	4
TX_CURR_DSD	Age/Sex: 20-24 Male	26





TX_CURR_DSD	Age/Sex: 25-49 Male	382
TX_CURR_DSD	Age/Sex: 50+ Male	130
TX_CURR_DSD	Age/Sex: 20-24 Female	300
TX_CURR_DSD	Age/Sex: 25-49 Female	2,526
TX_CURR_DSD	Age/Sex: 50+ Female	502
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,825
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	4
TX_NEW_DSD	By Age/Sex: 10-14 Male	7
TX_NEW_DSD	By Age/Sex: 15-19 Male	4
TX_NEW_DSD	By Age/Sex: 20-24 Male	31
TX_NEW_DSD	By Age/Sex: 25-49 Male	219
TX_NEW_DSD	By Age/Sex: 50+ Male	23
TX_NEW_DSD	By Age/Sex: 10-14 Female	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	29
TX_NEW_DSD	By Age/Sex: 20-24 Female	137
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,208
TX_NEW_DSD	By Age/Sex: 50+ Female	160
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,822
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	7
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	277
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	6
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,535
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,825
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,529
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,513
TX_PVLS_DSD	Numerator: Indication: Routine	3,401



TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	2,145
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	8
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	490
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	26
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	3,005
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	8
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	479
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	14
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	3,017
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,632
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,825
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	165



	months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	120
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,081
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	143
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	77
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of	4



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	215
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	133
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	1,170



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	175
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	249
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,411
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	277
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,535
------------	---	-------

### Implementing Mechanism Details

<b>Mechanism ID: 18213</b>	<b>Mechanism Name: Partnership with MOH on HIV/AIDS and TB Programs</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 6,357,688</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,357,688</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,357,688

### Cross-Cutting Budget Attribution(s)

Gender: GBV	156,442
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Gender: Gender Equality	156,442
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: MSM and TG	156,442
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Condom programming	312,884
Key Populations: FSW	312,884
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

**Budget Code Information**



<b>Mechanism ID: 18213</b>			
<b>Mechanism Name: Partnership with MOH on HIV/AIDS and TB Programs</b>			
<b>Prime Partner Name: Ministry of Health (MOH)</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	387,143	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	571,891	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	72,289	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,830,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount





Prevention	HVOP	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,076,730	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	911,201	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	108,434	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1,792
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,792
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,434
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	341
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	341
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	273
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	7
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	7
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7



LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	7
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	7
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1,500
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1,500
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,200
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	126
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	126
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	100
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	19
HRH_PRE	By Graduates: Doctors	7
HRH_PRE	By Graduates: Nurses	2



HRH_PRE	By Graduates: Midwives	0
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	4
HRH_PRE	By Graduates: Other	6
HRH_PRE	Sum of Graduates disaggreagtes	19

**Implementing Mechanism Details**

<b>Mechanism ID: 18214</b>	<b>Mechanism Name: Health Information Systems Innovations</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Palladium Group		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 3,900,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,900,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,900,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18214</b>			
<b>Mechanism Name: Health Information Systems Innovations</b>			
<b>Prime Partner Name: Palladium Group</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	3,900,000	0
------------------------	------	-----------	---

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	35

**Implementing Mechanism Details**

<b>Mechanism ID: 18215</b>	<b>Mechanism Name: Coptic Hospitals</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Coptic Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,341,355</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,341,355</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,341,355

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18215
<b>Mechanism Name:</b>	Coptic Hospitals
<b>Prime Partner Name:</b>	Coptic Hospital



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	808,767	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	254,639	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	147,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	169,184	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	827,662	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,903,560	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	230,301	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,050
PMTCT_ART_DSD	New on ART	488
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,384
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,050



PMTCT_STAT_DSD	Number of new ANC and L&D clients	12,050
PMTCT_STAT_DSD	By: Known positives at entry	1,600
PMTCT_STAT_DSD	By: Number of new positives identified	642
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,242
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	11
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	83
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	21
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	142
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	63
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	322
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	2,064
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	4,403
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	833
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	167
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	260
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	53



PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	63
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	322
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	2,064
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	4,403
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22,569
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	15,427
VMMC_CIRC_DSD	By Age: 15-19	4,172
VMMC_CIRC_DSD	By Age: 20-24	883
VMMC_CIRC_DSD	By Age: 25-29	875
VMMC_CIRC_DSD	By Age: 30-49	1,134
VMMC_CIRC_DSD	By Age: 50+	79
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	20,561
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	22,570
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	21,069
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,500
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	247,400
HTC_TST_DSD	Age/sex: 10-14 Male	1,189
HTC_TST_DSD	Age/sex: 15-19 Male	10,357
HTC_TST_DSD	Age/sex: 20-24 Male	21,646
HTC_TST_DSD	Age/sex: 25-49 Male	58,718
HTC_TST_DSD	Age/sex: 50+ Male	5,261
HTC_TST_DSD	Age/sex: 10-14 Female	1,437
HTC_TST_DSD	Age/sex: 15-19 Female	12,213
HTC_TST_DSD	Age/sex: 20-24 Female	26,200
HTC_TST_DSD	Age/sex: 25-49 Female	73,166



HTC_TST_DSD	Age/sex: 50+ Female	6,374
HTC_TST_DSD	Sum of Age/Sex disaggregates	216,561
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	65
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	297
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,550
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	165
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	8
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	120
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	521
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,704
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	281
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,572
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	96,750
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	14,886
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	124,192
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	26,458
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	220,942
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	247,400
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	221
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,356
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	389
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,178
HTC_TST_DSD	Test Result by Age: Positive: <1	2
HTC_TST_DSD	Test Result by Age: Positive: 1-9	124





HTC_TST_DSD	Age/sex: <1	1,033
HTC_TST_DSD	Age/sex: 1-9	19,006
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	13,775
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	145,328
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,559
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,953
HTC_TST_DSD	Service Delivery Point (Facility): VCT	60,980
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	4,908
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	13,776
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	540
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	3,581
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,254
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,254
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	48
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	629
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	39
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	538
GEND_GBV_DSD	Number of people receiving post-GBV care	126
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	88
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	38
GEND_GBV_DSD	By PEP service provision (related to sexual violence	38

	services provided)	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	759
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	759
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	383
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	329
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	67,218
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,390
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	20,682
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,256
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	41,891
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	13,445
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	12,102
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear	0



	only	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	12,102
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,444
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	290
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,734
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	20
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	23
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	67,218
TX_CURR_DSD	Age/Sex: 15-19 Male	1,012
TX_CURR_DSD	Age/Sex: 15-19 Female	1,780
TX_CURR_DSD	Sum of age/sex disaggregates	2,792
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,390
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	20,681
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,256
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	41,891
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,646
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	62,572
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	67,218
TX_CURR_DSD	Age/Sex: <1	30
TX_CURR_DSD	Age/Sex: <1-9	2,982
TX_CURR_DSD	Age/Sex: 10-14 Male	845
TX_CURR_DSD	Age/Sex: 10-14 Female	789
TX_CURR_DSD	Age/Sex: 20-24 Male	985
TX_CURR_DSD	Age/Sex: 25-49 Male	13,964
TX_CURR_DSD	Age/Sex: 50+ Male	4,720



TX_CURR_DSD	Age/Sex: 20-24 Female	3,610
TX_CURR_DSD	Age/Sex: 25-49 Female	30,482
TX_CURR_DSD	Age/Sex: 50+ Female	6,019
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,486
TX_NEW_DSD	By Age/Sex: <1	51
TX_NEW_DSD	By Age/Sex: 1-9	410
TX_NEW_DSD	By Age/Sex: 10-14 Male	63
TX_NEW_DSD	By Age/Sex: 15-19 Male	53
TX_NEW_DSD	By Age/Sex: 20-24 Male	175
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,002
TX_NEW_DSD	By Age/Sex: 50+ Male	486
TX_NEW_DSD	By Age/Sex: 10-14 Female	77
TX_NEW_DSD	By Age/Sex: 15-19 Female	243
TX_NEW_DSD	By Age/Sex: 20-24 Female	979
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,448
TX_NEW_DSD	By Age/Sex: 50+ Female	518
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,044
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	292
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,716
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	290
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,188
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,486
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	60,509
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	60,509
TX_PVLS_DSD	Numerator: Indication: Routine	60,509
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	60,509



TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,157
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	18,616
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,034
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	37,702
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,157
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	18,616
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,034
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	37,702
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,343
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,486
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	358
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	159
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,700
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and	440



	children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	216
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	883
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,892
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	463
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	391
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	63
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	53



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	175
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,002
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	486
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	77
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	243
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	979
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,448



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	518
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	269
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,350
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	270
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,454
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	292
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,716
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	7,188





	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

**Implementing Mechanism Details**

<b>Mechanism ID: 18216</b>	<b>Mechanism Name: UMB PACE Kamilisha</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 700,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	700,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18216		
<b>Mechanism Name:</b>	UMB PACE Kamilisha		
<b>Prime Partner Name:</b>	University of Maryland Baltimore		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	169,274	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	53,295	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	31,608	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	398,412	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	47,411	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18217</b>	<b>Mechanism Name: Ngima for Sure</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: County Government of Siaya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,822,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,822,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,822,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	637,700
Gender: GBV	45,550



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Gender: Gender Equality	45,550
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID:</b> 18217			
<b>Mechanism Name:</b> Ngima for Sure			
<b>Prime Partner Name:</b> County Government of Siaya			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	295,503	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	93,039	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	55,178	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	695,513	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	82,767	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,515
PMTCT_ART_DSD	New on ART	114
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	323
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,515
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,515
PMTCT_STAT_DSD	By: Known positives at entry	212
PMTCT_STAT_DSD	By: Number of new positives identified	74
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	286
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	10



	new positives: 20-24	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	28
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	14
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	72
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	457
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	972
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	153
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	30
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	54
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	9
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	14
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	72
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	457
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	972
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,051
HTC_TST_DSD	Age/sex: 10-14 Male	1,283



HTC_TST_DSD	Age/sex: 15-19 Male	939
HTC_TST_DSD	Age/sex: 20-24 Male	2,351
HTC_TST_DSD	Age/sex: 25-49 Male	3,758
HTC_TST_DSD	Age/sex: 50+ Male	939
HTC_TST_DSD	Age/sex: 10-14 Female	1,609
HTC_TST_DSD	Age/sex: 15-19 Female	1,323
HTC_TST_DSD	Age/sex: 20-24 Female	3,303
HTC_TST_DSD	Age/sex: 25-49 Female	5,295
HTC_TST_DSD	Age/sex: 50+ Female	1,324
HTC_TST_DSD	Sum of Age/Sex disaggregates	22,124
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	29
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	42
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	113
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	175
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	42
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	42
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	67
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	171
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	273
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	67
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,714
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,988
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,105
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,244
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	12,819
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	19,232
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	32,051
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	81



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	374
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	127
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	577
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	133
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	9,927
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,810
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	19,015
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	315
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	239
HTC_TST_DSD	Service Delivery Point (Facility): VCT	7,812
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	542
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	1,812
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	66
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	440
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	104
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	104
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	58
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	0



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	70
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	70
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	33
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,241
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	218
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,161
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	234
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,628
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	848





TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	764
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	764
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	237
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	85
PMTCT_EID_DSD	Sum of Infant Age disaggregates	322
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	9
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	9
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,241
TX_CURR_DSD	Age/Sex: 15-19 Male	31
TX_CURR_DSD	Age/Sex: 15-19 Female	55
TX_CURR_DSD	Sum of age/sex disaggregates	86
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	218
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,161
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	234
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,628
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	452
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,789
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,241
TX_CURR_DSD	Age/Sex: <1	4
TX_CURR_DSD	Age/Sex: <1-9	299
TX_CURR_DSD	Age/Sex: 10-14 Male	73
TX_CURR_DSD	Age/Sex: 10-14 Female	76



TX_CURR_DSD	Age/Sex: 20-24 Male	56
TX_CURR_DSD	Age/Sex: 25-49 Male	801
TX_CURR_DSD	Age/Sex: 50+ Male	273
TX_CURR_DSD	Age/Sex: 20-24 Female	232
TX_CURR_DSD	Age/Sex: 25-49 Female	1,956
TX_CURR_DSD	Age/Sex: 50+ Female	385
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,391
TX_NEW_DSD	By Age/Sex: <1	6
TX_NEW_DSD	By Age/Sex: 1-9	78
TX_NEW_DSD	By Age/Sex: 10-14 Male	24
TX_NEW_DSD	By Age/Sex: 15-19 Male	4
TX_NEW_DSD	By Age/Sex: 20-24 Male	31
TX_NEW_DSD	By Age/Sex: 25-49 Male	281
TX_NEW_DSD	By Age/Sex: 50+ Male	107
TX_NEW_DSD	By Age/Sex: 10-14 Female	19
TX_NEW_DSD	By Age/Sex: 15-19 Female	14
TX_NEW_DSD	By Age/Sex: 20-24 Female	80
TX_NEW_DSD	By Age/Sex: 25-49 Female	624
TX_NEW_DSD	By Age/Sex: 50+ Female	123
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,307
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	61
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	423
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	66
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	841
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,391
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,820
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,820



TX_PVLS_DSD	Numerator: Indication: Routine	3,820
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	3,820
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	197
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,045
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	211
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,367
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	197
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,045
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	211
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	2,367
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,289
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,389
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults)	259



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	573
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	113
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	78
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24



TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	281
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	107
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	80
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of	624



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	123
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	391
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	64
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	774
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	61
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	423
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	66



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	841

### Implementing Mechanism Details

<b>Mechanism ID: 18223</b>	<b>Mechanism Name: Kemri Non-Research</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,750,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,750,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,750,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	752,500
Gender: GBV	53,750
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	53,750
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID: 18223</b>			
<b>Mechanism Name: Kemri Non-Research</b>			
<b>Prime Partner Name: University of Maryland</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	145,092	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	45,682	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	27,092	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	1,550,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	941,496	0





Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	40,638	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18260</b>	<b>Mechanism Name: International AIDS Education and Training Center (I-TECH)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 350,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	350,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18260
<b>Mechanism Name:</b>	International AIDS Education and Training Center (I-TECH)
<b>Prime Partner Name:</b>	University of Washington



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	350,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18261</b>	<b>Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	50,000
----------------------------	--------

**Budget Code Information**

<b>Mechanism ID: 18261</b>
----------------------------



<b>Mechanism Name:</b> Quality Improvement Capacity for Impact Project (QICIP)			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	60,455	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	19,034	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	11,288	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	142,290	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	16,933	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18262</b>	<b>Mechanism Name: Strengthening Public Health Capacity and SI Systems</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18262		
<b>Mechanism Name:</b>	Strengthening Public Health Capacity and SI Systems		
<b>Prime Partner Name:</b>	UNAIDS - Joint United Nations Programme on HIV/AIDS		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18281</b>	<b>Mechanism Name: Kenya Supply Chain System Strengthening</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes

Approved



G2G: No	Managing Agency:
<b>Total All Funding Sources: 575,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 575,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	575,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 18281			
<b>Mechanism Name:</b> Kenya Supply Chain System Strengthening			
<b>Prime Partner Name:</b> Global Health Supply Chain Program			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	575,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18283</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

Approved



<b>Mechanism ID: 18284</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18285</b>	<b>Mechanism Name: Coordinating Comprehensive Care for Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18285		
<b>Mechanism Name:</b>	Coordinating Comprehensive Care for Children		
<b>Prime Partner Name:</b>	Catholic Relief Services		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	100,000	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18317</b>	<b>Mechanism Name: General Nursing Capacity Building Program</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:
<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18317		
<b>Mechanism Name:</b>	General Nursing Capacity Building Program		
<b>Prime Partner Name:</b>	Columbia University Mailman School of Public Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	100,000	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18318</b>	<b>Mechanism Name: County Measurement Learning &amp; Accountability Project (CMLAP)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,850,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,850,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,850,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18318		
<b>Mechanism Name:</b>	County Measurement Learning & Accountability Project (CMLAP)		
<b>Prime Partner Name:</b>	Palladium Group		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	2,850,000	0





### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18504</b>	<b>Mechanism Name: UMB Timiza</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 9,952,773</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 9,952,773</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	9,952,773

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18504		
<b>Mechanism Name:</b>	UMB Timiza		
<b>Prime Partner Name:</b>	University of Maryland Baltimore		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,770,633	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	557,481	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	330,621	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	1,154,192	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	457,139	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,019,310	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	4,167,465	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	495,932	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18505</b>	<b>Mechanism Name: CHS Shinda</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 13,515,808</b>	
--	--



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 13,515,808</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	13,515,808

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18505</b>			
<b>Mechanism Name: CHS Shinda</b>			
<b>Prime Partner Name: Center for Health Solutions (CHS)</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,026,962	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	856,292	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	507,836	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	2,052,700	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	649,783	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,259,241	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,401,239	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	761,755	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18506</b>	<b>Mechanism Name: UCSF Clinical Kisumu</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 8,359,914</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,359,914</b>	
Funding Source	Funding Amount
GHP-State	8,359,914

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 18506
----------------------------



<b>Mechanism Name:</b> UCSF Clinical Kisumu			
<b>Prime Partner Name:</b> University of California at San Francisco			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,096,897	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	345,356	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	204,818	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	2,354,092	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	649,815	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	819,990	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,581,719	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	307,227	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18507	<b>Mechanism Name:</b> CHS Tegemeza Plus
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,714,291</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,714,291</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,714,291

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18507		
<b>Mechanism Name:</b>	CHS Tegemeza Plus		
<b>Prime Partner Name:</b>	Center for Health Solutions (CHS)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,429,412	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	324,109	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	192,217	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	152,304	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	305,039	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,022,885	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	288,325	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18508</b>	<b>Mechanism Name: CHS Naishi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 7,667,571</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 7,667,571</b>	
Funding Source	Funding Amount
GHP-State	7,667,571

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18508			
<b>Mechanism Name:</b> CHS Naishi			
<b>Prime Partner Name:</b> Center for Health Solutions (CHS)			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	2,333,897	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	482,945	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	436,417	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	423,879	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	600,535	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,660,272	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	729,626	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18509	<b>Mechanism Name:</b> AMREF Nairobi Kitui
<b>Funding Agency:</b> HHS/CDC	<b>Procurement Type:</b> Cooperative Agreement





Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,380,424</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,380,424</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,380,424

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18509		
<b>Mechanism Name:</b>	AMREF Nairobi Kitui		
<b>Prime Partner Name:</b>	African Medical and Research Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	706,355	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	159,425	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	94,549	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	198,900	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	87,585	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	991,786	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	141,824	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18511</b>	<b>Mechanism Name: CHAK CHAP Uzima</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 7,400,770</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 7,400,770</b>	
Funding Source	Funding Amount
GHP-State	7,400,770

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	18511		
<b>Mechanism Name:</b>	CHAK CHAP Uzima		
<b>Prime Partner Name:</b>	Christian Health Association of Kenya		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,978,597	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	202,832	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	465,533	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	276,091	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	560,277	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	523,193	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,980,110	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	414,137	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 18512</b>	<b>Mechanism Name: UON COE Niche</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,997,545</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,997,545</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,997,545

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18512		
<b>Mechanism Name:</b>	UON COE Niche		
<b>Prime Partner Name:</b>	University of Nairobi		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	560,557	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	176,490	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	104,671	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	150,637	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	328,826	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,519,360	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	157,004	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18513</b>	<b>Mechanism Name: LVCT Steps</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,097,153</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,097,153</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,097,153

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18513			
<b>Mechanism Name:</b> LVCT Steps			
<b>Prime Partner Name:</b> Liverpool VCT and Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,588,318	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,090,675	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	118,160	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 18514	<b>Mechanism Name:</b> HWWK Nairobi Eastern
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 2,240,703	
<b>Applied Pipeline Amount:</b> 0	



<b>Total All Funding Sources and Applied Pipeline Amount: 2,240,703</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,240,703

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18514</b>			
<b>Mechanism Name: HWWK Nairobi Eastern</b>			
<b>Prime Partner Name: Hope Worldwide</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	171,538	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	36,820	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	345,917	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	1,139,638	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	271,540	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	275,250	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18515</b>	<b>Mechanism Name: Faith-Based Sites in the Eastern Slums of Nairobi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Deanery AIDS Relief Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,451,459</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,451,459</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,451,459

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18515		
<b>Mechanism Name:</b>	Faith-Based Sites in the Eastern Slums of Nairobi		
<b>Prime Partner Name:</b>	Eastern Deanery AIDS Relief Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,182,962	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Care	HVTB	297,303	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	175,422	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	860,756	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	272,851	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	412,976	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,983,812	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	265,377	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18516</b>	<b>Mechanism Name: Bomu Hospital Affiliated Sites</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mkomani Society Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,847,393</b>	
---	--



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,847,393</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,847,393

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18516</b>			
<b>Mechanism Name: Bomu Hospital Affiliated Sites</b>			
<b>Prime Partner Name: Mkomani Society Clinic</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	820,880	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	139,814	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	195,057	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	112,789	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	344,790	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	231,651	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	457,841	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,368,158	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	176,413	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18517</b>	<b>Mechanism Name: UOW Training</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
Funding Source	Funding Amount
GHP-State	500,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18517			
<b>Mechanism Name:</b> UOW Training			
<b>Prime Partner Name:</b> University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	120,910	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	38,068	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	22,577	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	284,580	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	33,865	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Agency Information - Costs of Doing Business**

**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount



Capital Security Cost Sharing		847,000		0	847,000	847,000
Computers/IT Services		500,500		0	500,500	500,500
ICASS		1,204,500		0	1,204,500	1,204,500
Institutional Contractors		1,355,462		751,849	1,355,462	2,107,311
Management Meetings/Professional Development		632,527		0	632,527	632,527
Non-ICASS Administrative Costs		749,586		0	749,586	749,586
Staff Program Travel		843,729		0	843,729	843,729
USG Staff Salaries and Benefits - Internationally Recruited		2,240,243		0	2,240,243	2,240,243
USG Staff Salaries and Benefits - Locally Recruited		3,772,669		0	3,772,669	3,772,669
<b>Total</b>	<b>0</b>	<b>12,146,216</b>	<b>0</b>	<b>751,849</b>	<b>12,146,216</b>	<b>12,898,065</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business
-------------------------------	-----	-----------	-----------	------------------	-------	----------------------------------



						Categories and Applied Pipeline Amount
Computers/IT Services		14,010		0	14,010	14,010
ICASS		138,542		0	138,542	138,542
Indirect Costs		467,649		0	467,649	467,649
Institutional Contractors		1,663,660		0	1,663,660	1,663,660
Management Meetings/Professional Development		166,207		0	166,207	166,207
Non-ICASS Administrative Costs		770,925		0	770,925	770,925
Staff Program Travel		778,048		0	778,048	778,048
<b>Total</b>	<b>0</b>	<b>3,999,041</b>	<b>0</b>	<b>0</b>	<b>3,999,041</b>	<b>3,999,041</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		255,805		0	255,805	255,805



Computers/IT Services		800,000		0	800,000	800,000
ICASS		1,400,000		0	1,400,000	1,400,000
Institutional Contractors		260,000		0	260,000	260,000
Management Meetings/Professional Development		96,925		0	96,925	96,925
Non-ICASS Administrative Costs		3,718,739		0	3,718,739	3,718,739
Staff Program Travel	0	1,576,850		0	1,576,850	1,576,850
USG Staff Salaries and Benefits - Internationally Recruited	3,320,000	478,333		0	3,798,333	3,798,333
USG Staff Salaries and Benefits - Locally Recruited	0	4,273,534		0	4,273,534	4,273,534
<b>Total</b>	<b>3,320,000</b>	<b>12,860,186</b>	<b>0</b>	<b>0</b>	<b>16,180,186</b>	<b>16,180,186</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied
-------------------------------	-----	-----------	-----------	------------------	-------	---



						Pipeline Amount
ICASS		0		264,937	0	264,937
Management Meetings/Professional Development		0		131,203	0	131,203
Non-ICASS Administrative Costs		0		27,000	0	27,000
Staff Program Travel		0		35,000	0	35,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		0		641,860	0	641,860
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,100,000</b>	<b>0</b>	<b>1,100,000</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount



Approved



Non-ICASS Administrative Costs		2,777		16,821	2,777	19,598
Peace Corps Volunteer Costs		88,984		557,527	88,984	646,511
Staff Program Travel		3,156		19,124	3,156	22,280
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		39,105		236,934	39,105	276,039
<b>Total</b>	<b>0</b>	<b>134,022</b>	<b>0</b>	<b>830,406</b>	<b>134,022</b>	<b>964,428</b>